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Abstract 
Obesity is a pathological condition characterized by an augmented presence of fat mass in 
the body. Obesity is known to increase the risk of many cancer types. Clinical data produced 
by ourselves and others have shown that the incidence of acute promyelocytic leukaemia 
(APL) is strongly correlated with obesity. The cytogenetic hallmark of APL is the reciprocal 
translocation between chromosomes 15 and 17 that fuses portions of the retinoic acid 
receptor α (RARα) and PML genes, resulting in the formation of the PML/RARα fusion 
protein. However, the molecular mechanisms explaining the effects of obesity on APL 
development have not been elucidated. 
To recapitulate clinical observations, we developed and characterized a mouse model of diet-
induced obesity using transgenic mice constitutively expressing PML/RARα in the 
hematopoietic system (PML/RARα KI mice) and wild type mice as a control. Mice were fed 
standard diet (SD) or high fat diet (HFD) (60% vs 10% of fats in the chow), and leukaemia-
free survival was monitored. As expected, we observed that HFD-fed PML/RARα KI mice 
developed leukaemia earlier (median survival 204 vs 254 days, p<0.001) and with higher 
penetrance (100% vs 70%) than SD-fed mice.  
By FACS analysis upon bone marrow (BM) subpopulations, we demonstrated that HFD 
increases the percentage of progenitor cells in both WT and PML/RARα KI, while 
concomitantly decreasing the percentage of hematopoietic stem cells (HSCs). Indeed, we 
demonstrated that this shift is mediated by a decrease in G0 phase in PML/RARα KI HFD-
fed mice, suggesting a loss of quiescence.  
We then evaluated the extent of DNA damage in hematopoietic stem cells (HSC) after four 
months of diet, using the comet assay. We demonstrated that that HFD-fed PML/RARα KI 
mice presented a 40% increase of DNA damage in HSCs as compared to SD-fed PML/RARα 
mice (p<0.001). However, this was not associated with an increased mutational load as 
revealed by a novel whole genome sequencing-based method. We investigated whether HFD 
confers a proliferative advantage to PML/RARα bone marrow using colony forming assays. 
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Indeed, we observed that HFD PML/RARα bone marrow has a higher clonogenicity than 
bone marrow from SD-fed mice.  
Finally, we demonstrated that linoleic acid (LA), which is the main component of HFD 
increases PML/RARα enhanced self-renewal via a mechanism that may be related to PPARd 
activation. 
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Chapter 1. Introduction 
 
1.1 Obesity and cancer 
Obesity is a pathological state characterized by increased body fat mass. Nowadays, it has 
become a serious problem worldwide: nearly two thirds of adults in the United States are 
overweight or obese1. Likewise, in the rest of the world the percentages are rising 
dramatically,  with projections of nearly 42% of the population being obese by 20302.  
The parameter most widely used to identify obese individuals is the Body Mass Index (BMI), 
which is defined as the ratio between the weight in kilos and the square of height in meters. 
Based on this formula, the World Health Organization (WHO) classifies individuals in 4 
different classes (table 1); with a BMI above 30 indicative of obesity3.  
BMI (Kg/m2) Weight category 
<18.5 Underweight 
18.5 to 24.9 Normal 
25.0 to 29.9 Overweight 
30.0 to 39.9 Obese 
>40 Severely Obese 
 
Table 1. BMI classification tables. On the left-hand side, the BMI values calculated as 
ratio between weight in kilos and height in square meters are reported, on the right-hand 
side - the weight category associated. 
The increased prevalence of obesity can be attributed to multiple causes, like increased 
caloric intake, snacking patterns of eating and decreased physical activity4,5. Additionally, 
genetic factors may also contribute to obesity6,7. Many genes have been correlated to 
increased body fat mass, most notably leptin and its receptor7. However, in humans 
mutations in leptin gene and its receptor are an extreme rare cause of obesity7. In fact, it was 
reported that obesity in humans can also be due to mutations in genes implicated in 
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alternative pathways, like appetite regulation by central nervous system (CNS), insulin 
action and glucose metabolism, and lipid metabolism8.  
Clinically, obese individuals can suffer from several diseases, most notably diabetes and 
cardiovascular diseases, configuring what is usually referred to as metabolic syndrome9.  
Mounting evidence also correlates obesity with risk of developing cancer. Experiments in 
the 50's showed that a mutation in the ob gene  (that codes in mice for leptin) correlated with 
increase in breast cancer risk10, due to uncontrolled estrogen production. Ten years later, this 
observations was confirmed in epidemiological studies assessing the prevalence of obesity 
in breast cancer patients11. Starting from these two pivotal observations, over the past 50 
years, numerous studies have established a strong correlation between obesity and risk of 
developing or dying of multiple tumor types such as liver, colon, ovarian and 
postmenopausal breast cancer7,12–14. 
Despite overwhelming epidemiological evidence, the molecular causes linking 
overweight/obesity and different tumors are still incompletely understood.  
The obese milieu is enriched for circulating factors like hormones, cytokines and 
chemokines that stimulate cell proliferation. Indeed, an additional source of growth-
promoting factors is the adipose tissue itself. These factors are generally known as 
adipokines such as adiponectin and tumor necrosis factor alpha (TNF-a). Adiponectin is 
secreted to signal satiety and enhances insulin sensitivity and glucose uptake15. In contrast 
to other adipokines, its expression is lowered in obese individuals16 and inversely correlates 
with cancer risk17,18. Multiple mechanisms have been hypothesized to explain adiponectin's 
anticancer activity: blocking vascular endothelial growth factor A (VEGF-A)19 in prostate 
cancer or mTOR signaling in colon cancer20. TNF-a role in cancer is quite puzzling, in fact, 
it was demonstrated that it may inhibit or sustain cancer growth depending on cancer type, 
stage and environment21,22. Brunn and colleagues demonstrated that in vitro TNF-a can 
reduce the mRNA levels of adiponectin, limiting its anti-cancer function23. However, Rubio 
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and colleagues have demonstrated that TNF-a reduced tumor mass by inducing tumor 
necrosis24.  
1.2 Epidemiological evidence in acute myeloid 
leukemia (AML) and acute promyelocytic leukemia 
(APL) 
 
Compared to solid tumors, in haematological malignancies the correlation between risk and 
obesity has been less studied. Moreover, in these studies, patients were rarely stratified 
differentiating chronic/acute and lymphoid/myeloid leukemias25.  
The first study in which obesity was linked to acute myeloid leukemia (AML) and chronic 
lymphoblastic leukemia (CLL) was performed on war veterans. In this study a strong 
association between obesity and AML and CLL was observed26. 
Larsson and colleagues conducted a meta-analysis of cohort studies published from 1966 to 
July 200727. The relative risk (RR) of developing disease for all subgroups (acute 
lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia 
(CML) and chronic lymphocytic leukemia (CLL)) was statistically significantly higher in 
obese compared to lean subjects: 1.65 (95% CI, 1.16–2.35) for ALL, 1.65 (95% CI, 1.16–
2.35) for AML, 1.25 (95% CI, 1.11-14), 1.26 (95% CI, 1.09–1.46) for CML and 1.25 (95% 
CI, 1.11–1.41) for CLL. 
Poynter and colleagues have specifically assessed the association between obesity and AML 
in a retrospective case-control study. In a cohort of 422 AML patients and 1388 controls, it 
was shown that obesity is associated in males and females with development of the disease 
(OR=2.22, 95% CI 1.28-3.85 for males and OR=1.85, 95% CI 1.08-3.15 for females)28.  
A more recent meta-analysis showed that in AML a modest but significant association 
between obesity and disease risk is repeatedly observed29, However, AML is increasingly 
understood as a disease whose natural history is strongly influenced by its underlying 
 15 
biology and genetics. Consequently, obesity may influence the risk of developing only some 
specific AML subtypes. Thus, I will now briefly review current AML classification systems 
before analysing the existing evidence on the association between obesity and specific AML 
subtypes. 
 
1.3 AML classifications 
 
Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults, it 
accounts for almost 80% of cases with acute leukemias30. The disease is characterized by an 
uncontrolled expansion of undifferentiated myeloid precursors that leads to impaired 
hematopoiesis. From the clinical point of view, AML patients present with anemia and 
thrombocytopenia. Physically, patients feel fatigue and weight loss. If uncured, this 
leukemia leads patients’ death in few months caused by severe bleeding or infections, due 
to severe impairment of immune function.  
AML is a very heterogeneous group of diseases; hence different classification systems have 
been devised. The earliest classification, still routinely used in the clinica, is the French-
America-British (FAB) system, based on morphological features31: 
More recently, the significant impact of the underlying genetic abnormalities has been 
recognized, prompting a new classification by the WHO  based on genetic features 32,33 . In 
2013, TGCA analyzed the genomes of 200 de novo cases of AML, using different genomic 
strategies e.g. whole-genome sequencing (WGS) or whole-exome sequencing (WES). It was 
discovered that in the analyzed patients the number of present mutations was much less 
compared to solid tumors, with an average of only 13 coding mutations (range 1 to 51)34. 
Acute promyelocytic leukemia (APL), which is the subject of this thesis, has distinct 
genetical and morphological features. This leukemia belongs to the M3 class in the FAB 
classification and is classified by the WHO as distinct class because of the presence of 
PML/RARa translocation.  
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From the genetic point of view, APL appears even less complex than AML. APL patients 
bear known translocations involving the retinoic receptor alpha gene (RARa) gene on 
chromosome 17. By far the most common (>99% of the cases) translocation partner is the 
promyelocytic leukemia (PML) gene, located on chromosome 15, resulting in the t(15;17) 
translocation. PML/RARa fusion mRNA was first cloned in 199135,36.  
Historically, it was a fatal and incurable leukemia subtype. If not treated, patients within few 
weeks, most often of bleeding due to severe thrombocytopenia.  
The introduction of all-trans retinoic acid (ATRA) into clinical practice in early ‘80s, 
constituted a turning point in the history of APL37. The molecule promotes differentiation of 
promyelocytes into mature granulocytes and its use is considered the paradigm of 
differentiation therapy. The first study in which ATRA was used in the clinics was performed 
in 198838. In this study, 22 APL patients were treated with ATRA, and 14 of them entered 
complete remission (CR) after the treatment. Following this first encouraging result, other 
clinical trials were conducted and confirmed the efficacy of ATRA. 
Arsenic trioxide, another important player in APL treatment, was first tested on humans in 
199039. In the first study 58 patients (11 de novo and 47 relapse APL) were treated with 
ATO. Eight out of 11 de novo and 40/47 relapsed patients obtained CR.  
Mouse models demonstrated that combination of ATRA and ATO synergized in APL. In 
fact, it was demonstrated that the two molecules eradicate the disease through the 
degradation of PML/RARa fusion protein40. 
With advances in treatment, APL, once considered the deadliest of all leukemia types, has 
become the most curable. Indeed, at present, APL is characterized by CR rates of 90% and 
cure rates of ∼80%, or even higher in low-risk patients41. 
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1.4 Clinical studies demonstrating association between 
APL and obesity 
 
The first study concentrating on obesity and AML subclasses was performed at the M.D 
Anderson Cancer Center on almost 1200 AML patients. Interestingly, only the incidence of 
acute promyelocytic leukemia (APL) correlated positively with obesity42 (p<0.0003). This 
first observation was corroborated by another study in China, in which the relationship 
between obesity and AML subclasses was analyzed in 29 hospitals in Shanghai43. The risk 
of developing AML was inversely correlated to BMI, whilst the risk of developing APL was 
positively correlated. These initial observations were confirmed by other studies 13,44,45, all 
with very small sample sizes. 
Our group independently studied the relationship between obesity and APL. In a first study 
on 120 APL patients14 it was demonstrated that following ATRA and idarubicin treatment, 
obese patients had a higher risk of relapse than normal-weight patients (hazard ratio 2.45 
95% CI, 1.00-5.99). 
Subsequently, we assessed the relationship between obesity and APL risk in a large 
unpublished study. We first reanalyzed the data by Bhaskaran et al13which comprises 5,833 
subjects with a diagnosis of "leukemia". This diagnosis was further classified into the 
following groups: "APL" (n=26), "non-APL-AML" (n=1,012), lymphoid leukemias ("LL"; 
n=2,823) and "other" (n=1,972). We observed that per each 5 kg/m2 BMI increase, we 
obtained HR of 1.44 for APL (95% CI 1.0-2.08), 1.17 for non-APL-AML (95% CI 1.10-
1.26), 1.04 for LL (95% CI 1.0-1.09) and 1.10 for other leukemias (95% CI 1.04-1.15). 
Stratifying by gender suggested a stronger effect for males in APL (HR 1.82, 95% CI 1.10- 
3.00 vs female (HR 1.19, 95% CI 0.67-1.98), although the sample numerosity became low 
(n=13 each). Together, these results imply that higher BMI is associated with increased risk 
of all sub-types of leukemia, particularly of APL. We then validated these results in 
retrospective case-control studies on cohorts obtained from   Spain (PETHEMA) and Italy 
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(GIMEMA) and patients from the USA-based AML genome sequencing study (the AML 
TCGA cohort with 22 additional cases characterized at Washington University-St Louis). 
To generate control groups for comparison, we obtained anthropometric data from 
epidemiological surveys of the general population in the different countries. In all three 
cohorts, there was a strong evidence that the observed BMI distribution for cases within the 
four WHO classes was different from that expected under the null hypothesis of no 
association (Italy p<0.001, Spain p=0.011, USA p<0.001) in gender-, age- and ethnicity- 
(for USA) matched controls. In particular, in all three datasets, there were more APL cases 
than expected in the high BMI groups, and less than expected in the low BMI groups. We 
then analyzed the transcriptomic profile of obese APL patients from the TCGA dataset. APL 
was associated with increased activity of 14 and decreased activity of 47 out of 186 
pathways. Intriguingly, pathways associated with the metabolism of long-chain unsaturated 
fatty acids (linoleic, linolenic and arachidonic acid, precursors of eicosanoids mediating 
inflammation-associated cancers), were among the top upregulated 
 
These data suggest that obesity influences APL onset and eventually tumor relapse, however 
the mechanisms at the basis of this relationship are unknown and are the major subject of 
this thesis work. 
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1.5 Genetics and biology of APL  
 
PML is a ubiquitously expressed nuclear protein that belongs to the TRIpartite Motif (TRIM) 
consisting of zinc RING finger, two alternate cysteine-histidine rich zinc binding domains, 
the B1 and B2 boxes, and an alpha-helical coiled-coil dimerization domain. Thanks to its 
conformation, PML forms particular structures in the cells known as nuclear bodies (NB)46–
48. PML gene in humans contains nine different exons spanning 53 kb. The messenger RNA 
can be spliced out into seven different variants. Six of the arising proteins, called (PML I-
VI), are nuclear, and, one called VIIb, is cytoplasmatic 49,50. In NBs, PML interacts with 
several proteins such as p53 and pRb that exert control over major cellular processes51. 
Indeed, NBs have been implicated in controlling cell cycle, apoptosis, senescence and, in 
general, all processes that regulate genome stability52,53. PML was shown to be a potent 
tumor suppressor. The lack of the protein in the PML knock-out mice accelerates 
spontaneously or after induction with X rays the development of different types of 
malignancies53–55   
Retinoic receptors (RAR) belong to the nuclear receptor family, comprising 3 members: a, 
b and g. RARa and RARg exert different function in the different phases of hematopoiesis, 
e.g. RARg alone is implicated in differentiation of hematopoietic stem cell56, while together 
with RARa is involved in the differentiation process of granulocytes57. Only RARa is 
crucial for APL development. RARa is a nuclear transcription factor that, in heterodimeric 
complex with retinoic X receptor (RXR), recognizes sequences of 6 bp (AGGTCA), 
separated by short spacers (1, 2 or 5bp) and named retinoic acid response elements 
(RARE)58. In the absence of its ligand, RARa is bound to RXR and the complex recruits 
histone deacetylase complexes (HDAC) such as nuclear receptor co-repressor complex 
(NCOR) and silencing mediator for retinoid or thyroid-hormone receptors (SMRT), so that 
transcription of downstream genes is blocked59. However, upon binding of its ligand, the 
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RARa recruits histone acetyl-transferase complexes (HAT) that ultimately leads to the 
transcription of downstream RARa targets60. 
The PML/RARa fusion protein works as a negative dominant protein for RARa as it has an 
increased binding affinity for the HDAC complexes61, in particular SMRT 62. Higher ligand 
concentrations are required to release the complex63. Therefore, PML/RARa and RARa 
compete for binding sites. Furthermore, the number of potential DNA binding sites of 
PML/RARa is higher than that of RARa. The protein, in fact, does not require the presence 
of RXR to bind DNA, is able to self-dimerize64,65 and to bind motifs which contain longer 
spacer regions66.  
The molecular mechanism of PML/RARa binding on RARE is better illustrated in figure 1. 
 
 
 
Figure 1. PML/RARa binding to RARE, modified from67. PML/RARa proteins (in light 
blue), in complex with RXR are binding retinoic acid response elements (RARE) (in violet 
rectangles. Upon binding, they recruit HDAC complex (in cyan) and transcription is 
repressed. 
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1.6 Cellular and mouse models to study APL 
 
Many cellular and mouse systems to model different aspects of APL and PML/RAR biology 
have been developed. Our group generated a cellular model in the U937 cell line (an AML 
cell line) that allowed inducible PML/RARa expression, which blocked differentiation upon 
different stimuli68. In 1996, Early and colleagues cloned PML/RARa under the Cd11b 
promoter and observed impaired myelopoiesis following mice irradiation. After irradiation, 
almost 100% of WT mice survived irradiation, while almost half of the transgenic mice 
carrying PML/RARa mutation died of leukopenia69. Two years later, Altabef and colleagues 
infected chicken embryos with a retrovirus carrying PML/RARa oncogene and observed the 
onset of leukemia in 2 weeks70.  
However, none of the two systems recapitulates completely the observations in patients. In 
1998, Grisolano and colleagues cloned human PML/RARa cDNA downstream of human 
Cathepsin G promoter (that ensures the expression only in promyelocytes and in 
progenitors71) and expressed it in transgenic mice72. Thirty percent of mice developed APL 
with clinical features compatible with those seen in patients. Low penetrance was attributed 
to low expression levels of the transgene. Therefore, in 2002, the same group generated a 
knock-in mouse model in which the cDNA was transcribed from mouse Cathepsin G 
promoter, increasing the expression of PML/RARa73. These new mice, in the C/57 
background (PML/RARa KI mice) developed APL with reduced latency (between 6-19 
months) and increased penetrance (60-70%) compared to the previous model. 
The incomplete penetrance and relatively long latency suggest that PML/RARa mutation is 
insufficient to give rise to the leukemia, and that at least a second oncogenic mutation is 
required. Many mutations cooperate with PML/RARa to give rise to leukemia, such as 
internal tandem duplication in the fms-like tyrosine kinase 3 gene (FLT3 ITD)74, or 
oncogenic K-ras75. Moreover, in 2011 Tim Ley’s group sequenced mouse APL genomes, 
and they observed that PML/RARa mutation occurred with mutations in different genes 
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often present in human APL, such as jak1 and lysine specific histone demethylase 6 (kmd6a). 
In particular they observed that jak1 mutation is also present in human APL76. More recently, 
in our group, Riva and colleagues sequenced the genome from 5 mouse APL and 11 human 
APL. They observed that in all mice 18 mutations were present in total, while in the human 
7377. 
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1.7 In vivo studies demonstrating association between 
obesity and APL 
 
The availability of a mouse model able to faithfully reproduce APL prompted us to test the 
effect of diet-induced obesity. To this end, PML/RARa KI mice were fed ad libitum with 
standard diet (SD, with 10% content made of fat) or high fat diet (HFD, 60% fat). As a 
control, WT mice were fed with identical dietary regimens.  
Weight gain was equal in both strains (Figure 2A). When mice were fed with HFD, the 
penetrance of the disease increased to 100% compared to 70% observed in SD. Moreover, 
the median survival dropped from 254 days in SD to 204 in HFD (p<0.001).  
Taken together, these data demonstrated that mice model expressing PML/RARa could be 
used as a model to understand the relationship between APL onset and obesity, which is the 
ultimate scope of this thesis work. 
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Figure 2. Obesity cooperates with PML/RARa mutation in APL development. A) 
Weight gain by the mice used in the experiments. On the x axis the weight is indicated in 
grams, on the y axis the days from diet beginning. WT SD is shown in magenta, WT HFD 
in green, PML/RAR KI (PRKI) SD in yellow, PML/RAR KI (PRKI) HFD in orange D B) 
Kaplan-Meier curve showing survival of 15 PML/RARa KI mice in SD (black line), 15 
PML/RAR KI mice in HFD (red line), WT SD mice black dashed line and WT HFD mice 
grey line. Percentage of survival is shown on the y axis, while days after treatment on the x 
axis.    
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Although the association between obesity and APL development is clear in patients and in a 
mouse model, convincing molecular theories explaining such cooperation are missing.  
Tabe and colleagues, showed that transcription of leptin overexpression is enhanced in APL 
cells. Moreover, when mesenchymal stem cell-derived adipocytes were co-cultured with 
APL cells, ATRA and doxorubicin lost their pro-apoptotic effect on APL cells78. However, 
the system used in this study does not mirror APL and our unpublished results do not support 
an overexpression of LepR in APL nor any correlation with obesity (not shown). 
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1.8 Architecture of hematopoietic system 
 
The history of study of the hematopoietic system has had a pivotal role in the understanding 
of the stem cells. Blood has an extremely high regenerative potential and it is estimated that 
every day bone marrow (BM) produces 1012  cells79 . Since the beginning of the XX century, 
it was postulated that hematopoietic system is organized in a hierarchical manner. The first 
piece of evidence for the hierarchy and, more in particular, for the existence of cells that 
generate other cells derived from an observation by Lorenz and colleagues in 195080. They 
observed that following irradiation, mice were able to survive only when transplanted with 
donor spleen or BM. However, this first observation did not fully explain whether there was 
only one cell or more cells giving rise to the fully reconstituted BM. Thanks to the 
development of flow cytometry, surface markers were discovered and hematopoietic stem 
cells (HSCs) characterized81. HSCs are on the apex of the hematopoietic cascade and are 
able to generate multipotent progenitors. In turn, the progenitors divide further giving rise 
to more differentiated cells. 
Since HSCs are extremely rare, both in mouse and in humans, the study of HSC biology has 
always been very difficult. Historically, HSCs to be defined must possess three different 
proprieties that historically were assessed only by transplantation: 
 a) it is capable of self-renewal. It indicates the ability of cells to divide maintaining the state 
of differentiation of the parent cell82. This propriety ensures the maintenance of the stem cell 
reservoir. On the contrary, differentiating potential indicates the capacity to produce mature 
cells upon appropriate stimuli82. Self-renewal and differentiation can be accomplished in a 
single mitosis event, in which a fate determinant is divided unequally in daughter cells giving 
rise to one differentiated and one stem cell (asymmetric stem cell division)82. To expand 
HSCs, a symmetric division is required, whilst to obtain committed cells, divisions with 
differentiation are needed82. Differences between symmetric and asymmetric stem cell 
division are illustrated in figure 3. 
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Figure 3. Asymmetric cell division and symmetric cell division modified from82. 
Schematic illustration of Asymmetric cell division (ACD) is shown on the left, in which a 
stem cell (SC) divides unequally into a new SC and a differentiated cell. On the right, 
symmetric cell division (SCD) is shown in which fate determinants are equally distributed 
giving rise to two identical daughter stem cells 
 
b) it can be dormant (a property also known as quiescence); 
 c) can enter an actively dividing phase83, differentiate and thus re-grow the cells forming 
the entire BM when recipient mice are irradiated for a long time (historically more than 12 
weeks84). The duration of engraftment upon transplantation has allowed for the distinction 
between long-term reconstituting HSCs, (LT-HSC), short-term reconstituting HSCs (ST-
HSCs) and multipotent progenitors (MPP).  
Once HSCs divide asymmetrically they generate all of the BM cells as illustrated in the 
figure 4.  
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Figure 4. Schematic representation of hematopoietic system, modified from85. On the 
top are shown long-term hematopoietic stem cells (HSCs). Division of HSCs gives rise to 
common myeloid progenitors (CMP), and common lymphoid progenitors (CLP). CMP in 
turn gives rise to monocyte, erythrocyte, neutrophils, eosinophils, megakaryocytes, mast 
cells, while CLP to B and T lymphocytes 
 
Differentiating cells lose self-renewal property and become more and more mature and 
specialized towards their ultimate function. This first model shown in figure 4 was defined 
as the “conventional” model. HSCs divide in a dichotomy fashion into common lymphoid 
and myeloid progenitors. This model was already discussed in the 80s and different 
observations, led researchers hypothesized a second model defined as “sequential 
determination model”86,87. This second model excludes a clear dichotomic choice of HSCs, 
but on the contrary supports the idea that HSCs undergo stepwise processes during 
maturation (Figure 5). 
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Figure 5. Sequential determination model, modified from88. HSCs can give rise to all 
cells in the BM through stepwise processes. 
 
Indeed, more recently Camargo group has published two different papers assessing 
hematopoietic cascade using transposons rather than transplantation. Actually, that 
progenitors are the drivers of complete hematopoiesis rather than HSCs. Moreover, they also 
suggest that progenitors are themselves capable of self-renewal, not only HSCs89,90. 
More recently, thanks to the development and the assessment of single cell RNA-seq in the 
BM, a new model was proposed. Based on this new model the maturation of HSCs occurs 
during a continuous process. Upon commitment, HSCs give rise to unilineage-restricted 
cells, which will give rise to differentiated cells. However, during this phase multi and 
bipotent stages were not clearly found91.  
 
Immature multipotent cells are defined by the lack of expression of the lineage (lin) markers 
and are referred to as lin- cells. Moreover, they express CD117 (c-Kit) and stem cell antigen 
1, also known as Sca-192. A population comprising lin- cells that express c-Kit and Sca1 is 
known as LKS population and contains HSC, which are marked with other two surface 
markers known as Cd150 and Cd4881,93. The two markers identify clearly stem cells (HSCs) 
and progenitors (MPP/HPC-1 and HPC2) as reported in figure 6. Oguro and colleagues 
performed functional transplantation of all these subpopulations into irradiated recipient 
mice and reported that only HSCs are capable of fully reconstituting irradiated BM. On the 
other hand, MPP, HPC-1 and HPC-2 are capable of short-term reconstitution of BM. In 
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particular, they showed that MPPs are capable of complete but transient BM reconstitution. 
HPC-1 cells instead contain mostly lymphoid progenitors and myelo-erythroid progenitors, 
while HPC-2 possess limited reconstituting potential for lymphoid progenitors. 
 
Figure 6. HSC gating strategy, modified from81. Representative FACS plot showing stem 
cell isolation (HSC). In the first panel are represented total bone marrow cells, 
undifferentiated cells are lineage negative (Lin-). In the second panel stem cells pool, LSK 
cells, are shown as c-KIT and and Sca-1 positive. In the third panel LSK are subdivided 
based on Cd48 and Cd150 markers in 4 quadrants, progenitors (MPP HPC1 and HPC2) and 
HSC. The arrows indicate the FACS parameters used to isolate the cells in each panel. 
 
In humans, the identification of HSCs does not parallel the mouse counterpart. Many surface 
markers which mark HSCs in human do not identify the mouse counterpart, and vice versa. 
For example, CD150 marks stem cells in mice but not in humans94. Therefore, further 
markers are necessary in order to isolate HSCs in humans. The first marker that was found 
was CD34 which marks HSCs95. This marker however could not be unique, because both 
progenitors and HSCs are CD34+. Therefore, in combination with CD34 also CD90 is 
currently used to isolate HSCs96.  
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1.9 Cellular metabolism of hematopoietic stem cells 
 
Stem cells reside in particular regions called “stem cell niches”, and in recent years the role 
of the metabolism appears to be fundamental for the fate of self-renewal or 
differentiation97,98. HSCs reside in the bone marrow cavity in a particular region called bone 
marrow niche. The cavity is hyper vascularized, although oxygen concentration inside is 
believed to be lower than in venous blood99. This was attributed to the concentration of 
oxygen which is consumed during proliferation of HSCs99. 
Therefore, HSCs in this region must rely on anaerobic glycolysis, in order to produce 
ATP100. Similarly, using a metabolomic/proteomic approach, Takubo and colleagues have 
shown that HSCs generate ATP through a mechanism relying on glycolysis101. The authors, 
in fact, observed high expression of the pyruvate dehydrogenase kinase enzyme in HSCs 
which inhibits the pyruvate dehydrogenase enzyme responsible of the conversion of 
pyruvate to Acetyl-coA necessary to enter Krebs’cycle102. 
A key player in the maintenance of anaerobic metabolism in HSCs is the hypoxia inducible 
factor 1 alpha (HIF-1a).  
The importance of HIF-1a and its fine-tuned expression in the HSCs maintenance was 
demonstrated in mouse models.  When HIF-1a is knocked-out it leads to the impairment in 
HSCs quiescence, leading to their differentiation and division. On the contrary, when VHL, 
the E3 biding HIF-1a, was knocked-out it led to the stabilization and maintenance of HSCs 
quiescence impairing HSCs’ capacity to repopulate the bone marrow upon 
transplantation103. Taken together, these data show the importance of the regulation of HIF-
1a expression: on the one hand its expression is fundamental for the maintenance of HSCs, 
on the other its expression must be regulated in order not to undergo stem cell exhaustion. 
Proliferation is a highly energy-consuming process. In terms of energy production, through 
anaerobic glycolysis two moles of ATP are obtained per one mole of glucose, instead, 
through the oxidative phosphorylation – 36 moles of ATP are obtained from the same 
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amount of glucose. Since ATP levels are much higher in progenitor cells104 compared to 
progenitors, it was proposed that mitochondrial activation plays a crucial role during stem 
cell differentiation. 
Thus, the switch from an anaerobic metabolism to OXPHOS metabolism is a fundamental 
step during differentiation. Together with ATP requirement, cells require also biomolecules 
like amino acids, lipids and nucleotides. Most of these molecules are biosynthetized de novo 
using different intermediates of TCA cycle. Mitochondria in the HSCs are smaller and less 
active compared to those in progenitors101, although their number does not change105.  
Mitochondria activity in progenitors and HSCs was studied by Yu and colleagues. In a 
mouse model of conditional inactivation of PTPMT1 protein, a PTEN-like mitochondrial 
phosphatase, resulted in the lack of differentiation of HSCs and consequently in bone 
marrow failure106.  
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1.10 Fatty acid metabolism and linoleic acid metabolism 
 
Fatty acids play multiple essential roles in biology. Besides their activity as energy source, 
they are the major component of membranes and are involved in signal transduction.  
The catabolism of FAs (fatty acid oxidation, FAO) occurs in the mitochondria and in the 
peroxisomes, depending on the length of their chain and is called, alpha in peroxisomes and 
beta in mitochondria. The two organelles use similar reactions to metabolize FAs, with few 
differences: firstly, mitochondria degrade bulk of short-, medium-, and long-chain FAs, 
while peroxisome degrade very long chain FAs; secondly, during the first metabolic 
reaction, the substrate is oxidized but the electron acceptor is different: in mitochondria FAD 
is reduced to FADH2, while in peroxisomes O2 is reduced to H2O2. Thus, this reaction 
creates reactive oxygen species, which could increase DNA damage as will be illustrated in 
the next section.  
Cells may choose between FAO and glucose consumption, and the choice between the two 
strategies derives from the organism status. In normal feeding conditions, cells prefer 
glucose metabolism and FAs are stored. 
Fatty acids can be classified in saturated and mono- or poly-unsaturated. Linoleic acid, 
central to the present project, is a polyunsatured omega-6 fatty acid with 18 carbon atoms. 
It must be introduced through diet as the human organism lacks essential enzymes for its 
synthesis107. Linoleic acid (LA) can be converted by enzymatic reactions into arachidonic 
acid (AA, 20:4) and eicosapentaenoic acid (EPA). AA and EPA are fundamental precursor 
for intermediate signaling mediators like prostaglandins (PG), leukotrienes (LT), 
thromboxanes (TX), which are important in inflammation and as sensor molecules. 
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1.11 Fatty acid metabolism in stem cells 
In different models, a crucial role of FAO in the regulation of stem cells was shown. For 
example, Knobloch and colleagues have demonstrated that in neural stem cells the 
impairment of FAO leads to cell death and lack of differentiation108. Beyaz and colleagues 
have shown that upon HFD intestinal stem cell (ICS) numbers are increased. The finding 
was corroborated in vitro by the demonstration that upon treatment with palmitic acid, the 
number of ISCs increased compared to control98. More recently, it was demonstrated that 
FAO regulates the homeostasis of ISCs109. They showed that upon inhibition of CPT1, the 
first enzyme in FAO cascade, the number of ISCs decrease dramatically.  
Regarding HSCs, Ito and colleagues have shown a role of FAO regulation in the balance 
between symmetric/asymmetric stem cell division97. They demonstrated that PML regulates 
peroxisome proliferator activator receptor delta (PPARd), and PPARd in turn activates FAO. 
This activation influences the balance between symmetric/asymmetric stem cell division. In 
fact, upon PML knock-out or FAO inhibition HSCs give rise to two committed cells, while 
using PPARd agonist, HSCs divide giving rise to two stem cells. More recently, it was 
discovered that PPARd-FAO axis stimulates mitochondria autophagy (mitophagy) which 
promotes HSC self-renewal110. 
 
In order to understand the role of polyunsaturated FA (PUFA), and in particular of LA in 
HSCs, it is important to pinpoint the way LA is metabolized before going into the details of 
its function.  
In general, LA is fundamental as it regulates the formation of messenger molecules such as 
prostaglandins, tromboxanes. Studies on the role of LA in HSCs have been mainly 
performed using PG. Porter and colleagues reported that treatment of mice with PGE2 
increased the number of HSCs. This increased number of HSCs does not derive from an 
increase in proliferation, but instead from a fact that PGE2 inhibits their apoptosis111.  PGE2 
was demonstrated to exert effects also in other stem cells types. Yun and colleagues 
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demonstrated that PGE2 increases the proliferation of embryonic stem cells and 
mesenchymal stem cells. In that settings, a shift towards S-phase, pushing cells into 
proliferation caused by PGE2 was observed112.  
 
1.12 Fatty acid metabolism in cancer cells 
 
Over the past 60 years, lipid metabolism in cancer has attracted a substantial amount of 
attention. As early as in 1950, it was observed that cancer cells synthetize de novo FA113. 
This observation is in agreement with the idea that cancer cells require lipids to store energy 
but also for the synthesis of membranes. One of the main observation in cancer is that the 
balance between the consumption of FA (FAO) and FA synthesis is shifted toward the 
synthesis. This leads to the accumulation of free FA in the organism that was observed in 
many tumor types ranging from colon and breast to brain cancer 114,115. In particular, in 1994 
FA synthase (FASN) was proposed as a diagnostic marker116. The upregulation of FASN 
was later observed in other tumor types such as prostate cancer 117. Moreover, recent studies 
have shown that deletion of the short arm of chromosome 8, a common feature in breast 
cancer, leads to enhanced FASN activity118. 
Regarding the role of FA metabolism in the progression of cancer, several groups have 
demonstrated a clear correlation between FAO and cancer progression. Pandolfi group 
established a correlation between FAO and breast cancer progression 119 showing that PML 
gene stimulates activation of FAO, which in turn stimulates breast cancer growth and 
anoikis. 
Moreover, as explained in the previous paragraph, LA metabolism can give rise to PGs that 
may be involved in the maintenance of HSCs. However, the same compounds may play a 
cancer-promoting role, as in the case of colon cancer where PGE2 triggers cell proliferation 
by activating the MAPK120.  
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1.13 Metabolism-induced oxidative stress and DNA 
damage 
 
DNA damage can be defined as alterations of the DNA structure produced by physical or 
chemical agents. DNA damage triggers a particular response (DNA damage response, DDR, 
is illustrated in figure 7). When double-stranded DNA damage is present, it is sensed by 
specialized sensors (DNA-damage Checkpoint 1, MDC1 and p53-binding protein 1, 53BP1) 
which activate the ataxia-telangiectasia mutated (ATM) kinase, that phosphorylates the 
H2AX histone, to form γH2AX. This in turn recruits more ATM, giving rise to a positive 
feedback loop increasing both ATM and γH2AX at sites of DNA damage. 
In the case of single-stranded break, single-stranded DNA-binding protein replication 
protein A (RPA) binds the site and recruits another complex named ataxia-telengiectasia and 
Rad-3 related (ATR), which phosphorylates H2AX in γH2AX. However, in ATR addition 
signal boosters are RAD9, RAD1 and HUS1, and by topoisomerase-II-binding protein 1 
(TOPBP1) and claspin. 
Cells tolerate a certain threshold of DNA damage, however when this threshold is exceeded, 
ATR and ATM phosphorylate CHK1 and CHK2 checkpoint kinases respectively. The two 
proteins diffuse through nuclear pores and interact with cellular fate mediators such as p53 
and CDC25 leading either to cell death or to repair of the damage. 
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Figure 7. DDR cascade modified from121. DDR cascade is shown in this figure. On the 
left, double strand breaks triggering ATM response are shown, while on the left single strand 
breaks triggering ATR response. 
  
The choice between the different DDR mechanisms depends on the state of the cell cycle, 
cell and damage type. When single- or double-stranded breaks occur in G1 phase, cells use 
non-homologous end-joining (NHEJ), in which broken DNA ends are bound by Ku70/80 
and recruit DNA dependent protein kinase (DNA-PK) and DNA ligase XRCC4 that repair 
DNA breaks without keeping genetic information, possibly giving rise to genomic 
instability122. The same type of damage during S-phase is repaired by homologous direct 
repair (HR) which is based on the exchange of genetical information by sister chromatids, 
ensuring the maintenance of genetic information122. Missmatch repair (MRR) enzymes 
recognize distortion of the DNA structure (possibly loops) which may derive from wrong 
incorporation of bases during DNA synthesis. The key mechanism was identified clearly in 
prokaryotes, and it is based on the recognition of parental strand (which is methylated) from 
the newly synthetized strand (not methylated). When this is present, an endonuclease cuts 
the DNA at the site of the distortion and an endonuclease digests the mismatched 
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nucleotides. Finally, DNA polymerase resynthesize the strand and ligase closes the gap. In 
eukaryotes, the repair process works in the same manner as in prokaryotes, however, it is 
less clear what is the signal that activates MRR123. 
When, instead, small insertion, deletion or wrong base incorporation is present, they are 
repaired by nucleotide excision repair (NER), mismatch repair (MMR) and base excision 
repair (BER). The NER pathway is activated when cells are exposed to irradiation leading 
to the formation of pyrimidine dimers, which block the DNA polymerase leading to fork 
stall124. BER is mediated by DNA glycosidase and is activated when bases are oxidized, 
deaminated and alkylated. In this pathway, the modified base is removed, then the correct 
base is inserted and finally ligated124.  
The BER mechanism has great importance in the field of metabolism, because it is the 
primary response to ROS attack in the cells. ROS in the cells can generate more than 100 
different lesions125. In particular, one of the most common types of DNA lesions caused by 
ROS oxidation is the formation of 8-oxoguanosine (8-oxoG). This type of lesion is very 
common due to guanosine low redox potential and when unrepaired can cause transversion 
from G:C to T:A. BER is the primary mechanism by which cells repair 8-oxoG and it is 
critical for genome maintenance126. 
Another type of lesions in which BER is crucial is the formation of 3-(2-deoxy-β-D-erythro-
pentofuranosyl)pyrimido[1,2-α]purin-10(3H)-one (M1dG) adducts, which will be discussed 
in this thesis work. M1dG originate from condensation of guanosine with a molecule of 
malondialdehyde. This molecule is the final product of lipid peroxidation in the cells, which 
as demonstrated, is enhanced in obese patients127. If not repaired by BER, M1dG formation 
causes transversion as well from C:G to A:T128.  
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1.14 Metabolism induced oxidative stress and DNA 
damage in stem cells 
 
As described in the previous paragraph, metabolism per se has a strong role in the fate of 
stem cells83. Before going deeply in the role of metabolism in DNA damage in stem cells, it 
is necessary to underline key concepts regarding DNA damage and HSCs. Firstly, recent 
evidence shows that cells can handle DNA damage in significantly different ways. Stem 
cells preferentially use NHEJ129, an error-prone repair modality, but are also able to tolerate 
higher amounts of DNA damage, accumulating it with aging by virtue of their long life span 
130. Furthermore, in a work from our group it was also shown that upon ionizing radiation, 
stem cells leave quiescence to expand progenitors131. This observation can be linked to 
another by Weissman group in which it was demonstrated that knock out of repair proteins 
affects self-renewal potential and leads finally to functional exhaustion132. 
In this scenario, oxidative stress induced by metabolites can play a key role. Two recent 
works by KJ Patel group have demonstrated that combined ablation of aldehyde-
metabolizing activity and DNA damage repair leads to bone marrow failure or leukemia 
upon transplantation133,134. Indeed, aldehydes, producing in the metabolism of ethanol and 
other endogenous and exogenous alimentary substances, directly induce DNA damage.  
  
 40 
1.15 Metabolism induced oxidative stress in cancer 
 
In normal cells, the perfect balance between ROS generation and degradation is maintained 
by the ROS degradation machinery. These ROS are generated during the mitochondrial 
OXPHOS reactions and are neutralized by several proteins in the cells such as superoxide 
dismutase (SOD), catalases, glutathione machinery, but also cofactors such as vitamins135. 
Whenever these processes do not occur properly, ROS may undergo several reactions in the 
cells damaging DNA. As discussed before, ROS can lead to lipid peroxidation leading to the 
formation of malondialdehyde which can bind DNA forming M1dG.  
However, also proteins can be attacked forming a particular adduct called 4-hydroxynonenal 
(4-HNE)136. This protein modification may alter correct protein function, leading to 
malignant transformation without altering DNA structure137.  
Indeed, in other different works, it was shown that ROS may modify protein structure 
leading to mutations which can modify specifically several pathways such as pathways 
controlling cell proliferation like ERK pathway. In particular, it was shown that ROS may 
activate different components of ERK pathway leading to its constitutive activation. For 
example, it was observed that nitrogen reactive species can specifically modify RAS 
structure leading to the formation of constitutively active form of the protein138. Differently, 
it was demonstrated in ovarian cancer that a phosphatase which acts negatively on ERK 
pathway can be modified by high oxygen species losing its controlling effect139. Therefore, 
treating cells with ROS scavengers, was proposed as a clinical strategy to decrease 
tumorigenesis, as demonstrated in breast cancer cell lines140. 
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Chapter 2. Aim of the work 
We and others have demonstrated that APL is associated with obesity and that this 
association can be reproduced using a mouse model of APL. The molecular mechanisms 
explaining this association are not completely elucidated. 
The scope of this thesis work was to define the molecular mechanisms linking obesity to 
APL onset using genetic, genomic and biochemical approaches. 
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Chapter 3. Materials and methods 
3.1 Cell lines 
For the maintenance of HSCs in culture Lin- medium was used, containing 90%RPMI 
(Euroclone), 10% FBS for stem cell maintenance (STEMCELL Technologies), 1% 
Penicillin/Streptomycin (Euroclone), 2 mM Glutamine (Euroclone), 100 µg/ml SCF 
(Peprotech), 10 µg/ml IL3 (Peprotech) and 10 µg/ml IL6 (Peprotech).  
 
3.2 In vivo experiments 
3.2.1 Mice strains 
Experiments involving mice were performed according to Italian law and following an 
approval of the Institutional Review Board and the Italian Ministry of Health (projects 
1072/15 and 967/17). PML/RARα knock-in mice were provided by T.J. Ley73 and 
backcrossed in C57BL/6J background. All wild type mice used in the study were purchased 
from Charles River: C57BL6/Ly5.2 and C57BL6/Ly5.1. Animals were bread and housed in 
Specific Pathogen-Free the animal facility at the European Institute of Oncology (IEO) and 
Institute FIRC of Molecular Oncology (IFOM) campus. Animal received ad libitum food 
and drinking water, and were kept in a regimen of 12-hour light-and-darkness cycle.  
 
3.2.2 Feeding regimens 
Animals were fed with ad libitum SD or HFD (Broogarden, D12492) starting from 8-12 
weeks of age. Mice were weighted at the beginning of the experiment and at the time of 
sacrifice. 
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3.2.3 Leukemia development 
To monitor leukemia development, peripheral blood (PB) was taken periodically (at least 1 
per month) from a small incision of the lateral caudal vein. Before the blood sampling, 
animals were heated up by an ultra-red light to dilate the veins. A volume of 100 µl of PB 
was taken from each animal and was mixed with 20 µl of 0.5M EDTA in order to prevent it 
from clotting. Animals were euthanized by CO2 inhalation when signs of suffering and 
distress were apparent. 
 
3.2.4 Bone marrow transplantation and competitive repopulation assay 
 
For BM transplantation, the procedure occurred in two different stages. The night before the 
transplantation, recipient animals were X-ray irradiated with a lethal dose irradiation of 8.5 
Gy. This procedure ensures that the recipients’ BM is depleted by irradiation, and 
consequently that the donor cells can proliferate in the empty BM niches. Soon after 
irradiation, in order to avoid infection due to immune-suppression neomycin (Sigma-
Aldrich) was added to drinking water at a final concentration of 1 mg/ml for two weeks 
following irradiation. The day after, intravenous (IV) transplantation was performed.  
For the competitive BM repopulating assay, BM cells deriving from donor (Ly 45.2 allele 
variant) and recipient mice (Ly 45.1 allele variant) were mixed together in a 1:9 ratio. In 
detail, 1*105 total BM cells deriving from obese/normal-weight PML/RARa mice (Ly 45.2) 
and 9*105 total BM cells of competitor mice (Ly 45.1) were transplanted into recipient 
Ly45.1 mice. Cell mixture was resuspended in phosphate buffered saline (PBS) and 
transplanted into the lateral caudal vein. After one month, engraftment was evaluated as the 
ratio of Ly 45.1/ Ly 45.2 in the PB. Following the transplantation, mice were all fed SD 
independently of the diet that was fed to the donors.  
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3.2.5 N-acetylcysteine treatment 
 
N-acetylcysteine powder (Sigma-Aldrich) was dissolved in sterile drinking water at a final 
concentration of 10 mg/ml. Bottles containing fresh NAC-supplemented water were changed 
twice a week together with food change. Animals were weighed at day 0, and every week 
for one month. After that mice weight, was assessed at 8 weeks, three months and at the 
sacrifice. 
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3.3 Flow cytometry  
 
Flow cytometry is a widely used imaging technique to analyze cells based on morphological 
and protein expression features. Flow cytometers detect and measure fluorescence intensity. 
The source of fluorescence is that of a fluorescent reporter- or selection protein expressed 
by the cell itself upon transduction or genetic modification (such as GFP), fluorochromes 
conjugated to antibodies that detect antigens present in/on cells, or fluorescent molecules 
with affinity for a particular ligand (e.g. DNA-binding DAPI or Propidium Iodine dyes). 
During FACS acquisition cells must be resuspended as a single-cell solution. When cells 
pass through the nozzle, the fluid sheath induces them to move from a turbulent regimen to 
a laminar regimen and can be scanned one by one by the laser. 
The first parameter which can be evaluated by FACS analysis is the morphology of the cells. 
When cells are hit by the laser, light scatters in all of the directions, and detectors measure 
the scattering. Two physical parameters can be detected by the detectors: side scatter (SSC) 
and forward scatter (FSC). SSC measures the granularity of the cells, while FSC corresponds 
to their size. For fluorescent marker detection, the laser excites the fluorophores with specific 
wavelengths. If the wavelength is coherent with the excitation spectrum of the fluorophore, 
the electrons of the fluorophore pass from the ground state to the excited state. The electrons 
then fall back and return to their ground state and energy is transferred in the form of a 
photon with has its own wavelength, usually different from the exciting one (emission 
spectrum). 
The wavelength produced by the emission is captured by photomultipliers which convert the 
signals in digital data. 
In this project, FACS analysis has been performed on mouse BM in order to purify and 
quantify the HSC population.  
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3.3.1 Antibodies used 
For the analyses the following fluorophore-conjugated antibodies were used: 
 
Antibody target Fluorophore Producer and catalogue number 
Gr-1 Pe-Cy7 
Thermo-Fisher Scientific 
#12-9668-82 
Cd3e Pe-Cy7 Thermo-Fisher Scientific #25-0031-82 
Cd45R(B220) Pe-Cy7 Thermo-Fisher Scientific #25-0452-82 
Cd11b Pe-Cy7 Thermo-Fisher Scientific #25-0112-82 
Ter-119 Pe-Cy7 Thermo-Fisher Scientific #25-5921-82 
Sca-1 PerCP 5.5 Thermo-Fisher Scientific #45-5981-82 
c-Kit APC Thermo-Fisher Scientific #17-1172-82 
Cd150 PE Thermo-Fisher Scientific #12-1502-82 
Cd48 Biotin Thermo-Fisher Scientific #13-0481-85 
Streptavidin 
Pacific blue Thermo-Fisher Scientific #48-4317-82 
BV605 
Beckton Dickinson 
#563260 
Cd45.1 Fitc Thermo-Fisher Scientific #11-0453-82 
Cd45.2 PE Thermo-Fisher Scientific #12-0454-82 
Table 2. List of antibodies used in the experiments 
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For each experiment, cells were compared to appropriate controls such as an unstained 
sample, in order to check autofluorescence, a sample stained with single antibodies, in order 
to check the positivity for each antibody alone and set the compensation of the machine, and 
a sample stained with all antibodies except one (all minus one), in order to establish gating 
strategies. 
 
3.3.2 Sample preparation 
At sacrifice the two hind limbs of the animal were removed and put in ice-cold PBS. Under 
a sterile hood, tibia and the femur of the animal were cleaned off the flesh by rubbing with 
a gauze and put in a 60mm dish containing 5 ml of ice-cold PBS supplemented with 1% 
penicillin/streptomycin and 2% of FBS. BMNC were obtained by flushing the bones with 
PBS in a 1ml syringe. Cells were then centrifuged 1200 rpm at 4°C for five minutes. In order 
to remove erythrocytes cells were incubated with red cell lysis buffer (155 mM NH4Cl, 12 
mM NaHCO3, 0.1 mM EDTA) for 2 minutes on ice. After incubation, cells were centrifuged 
again at 1200 rpm at 4°C for five minutes and cells are passed through a cell 40 µm strainer, 
in order to remove clumps and red cell debris. Cells were then counted following staining 
with Trypan-blue reagent (Sigma-Aldrich) at a dilution of 1:100.  
 
3.3.3 HSC gating strategy/isolation 
BMNC were resuspended at a final concentration of 100*106/ml and antibodies mix was 
added. In order to isolate HSCs, SLAM isolation markers were used: Lineage antibody 
cocktails (Cd3e, Cd11b, Gr-1, Ter-119 and Cd45R) used at 1:100 conjugated directly with 
PeCy7, Sca-1 used at 1:100 conjugated directly with PerCP5.5, c-Kit used at 1:100 
conjugated directly with APC, Cd150 used at 1:200 conjugated directly with PE, Cd48 
conjugated with biotin used at 1:100. Staining was performed for one hour at 4°C and after 
that excess of antibodies was removed by centrifuging twice the cells. Finally, Pacific Blue-
conjugated streptavidin as a detection reagent was used at 1:200 for one hour at 4°C. After 
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staining, cells were washed twice with ice-cold PBS supplemented with 2% FBS and 
resuspended in ice-cold PBS supplemented with 2% FBS at a final concentration of 
15*106/ml cells in FACS tubes, to be sorted by FACS Fusion (BD Bioscience). For HSCs 
isolation the following combination of markers were used Lin-Sca+c-Kit+Cd150+Cd48-93. 
Cells were initially gated based on SSC-H (height) versus SSC-A (area) in order to discard 
cell doublets. The positive population was then gated based on the morphological parameters 
using FSC and SSC. 
In order to distinguish various populations in the bone marrow a staining is performed with 
a cocktail of antibodies and cells are sequentially analyzed using a defined gating strategy. 
First of all, lin- negative cells are identified. Next, within the lin- population, c-Kit and Sca-
1 positive cells are gated on. Finally, the expression pattern of Cd50 and Cd48 is used to 
distinguish HSC (Cd150+/Cd48-), MPP (Cd150-/Cd48-), HPC-1 (Cd150-/Cd48+) and HPC-
2 (Cd150+/Cd48+)81 Sorting acquisition was performed at FACS Fusion (BD Bioscience). 
Analysis of the FACS were performed using FlowJo X software. 
 
3.3.4 Cell cycle  
For cell cycle analysis, 5*106 total BM cells stained for Lin/Sca/c-Kit/Cd150 and Cd48 were 
fixed for 10 minutes in 4% paraformaldehyde (PFA) on ice. After incubation cells were 
washed twice in ice-cold PBS. Cells then were permeabilized in 200 µl CytoFix/CytoPerm 
solution (BD Bioscience) for 10 minutes on ice. Cells were then resuspended in Washing 
buffer (BD Bioscience) and stained with FITC-conjugated KI-67 antibody (BD Bioscience) 
for 45 minutes on ice in the dark at a final concentration of 1:50. After staining, the excess 
of antibody was removed by washing cells once in Washing buffer. After wash, cells were 
incubated with DAPI solution (Sigma-Aldrich) resuspended at final concentration of 2 µg/ml 
and stained overnight at 4°C. 
The following morning, FACS samples were read on FACS Celesta II (BD Bioscience) 
instrument. Cells were discriminated based on DAPI-H (height) versus DAPI-A (area) in 
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order to discriminate the cell doublets. After stem cell isolation, as shown in the previous 
paragraph, cell cycle was measured using KI-67 vs DAPI. Cells low for both markers are in 
G0 phase, cells positive for KI-67 but low for DAPI are in G1 phase, whereas double positive 
cells are in S/G2/M phase. Analysis of the samples was performed using FACS DIVA 
software (BD Bioscience). 
 
3.3.5 Peripheral blood engraftment analysis 
PB sampled from the animals was centrifuged at 1200 rpm for 5 minutes. Cell pellets were 
then treated thrice with red blood cell lysis buffer and every time lysis buffer was inactivated 
with identical volume of PBS supplemented with 2% FBS. Finally, cells were resuspended 
in 250 µl of FBS-supplemented PBS.  
Staining was performed using an anti-Cd45.1 antibody conjugated with FITC and anti-
Cd45.2 antibody conjugated with PE each one diluted 1:100. Staining was performed for 1 
hour at 4°C, then excess of antibody was removed by centrifuging twice at 1200 rpm for 5 
minutes. Acquisition of samples was performed on FACS Celesta II (BD Bioscience). The 
analysis of the results was performed using FlowJo X software. 
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3.5 M1dG detection 
For M1dG detections, 3 WT mice kept in SD and HFD were sacrificed. BM cells were 
isolated as shown in the 3.3.2 section. M1dG was measured only in differentiated (Lin+) and 
undifferentiated (Lin-) BM portion due to amount of DNA required. Procedures are 
described in details in141. Briefly, genomic DNA was extracted from cellular pellet. DNA 
was then fragmented into single nucleotides and M1dG nucleotides were detected via 
chromatography. 
 
3.6 Alkaline Comet assay 
Alkaline Comet assay is a technique that is widely used in order to detect DNA damage. 
This technique compared to neutral comet assay offers the advantage of discriminating both 
single stranded breaks (SSB) and double stranded breaks (DSB). In this technique cells are 
blocked in agarose matrix and put on a microscopy slide. After cell lysis, naked DNA is 
subjected to an electrophoretic run. After the run, DNA is stained and thus, it is possible to 
follow the path of electrophoresis of DNA in the agarose matrix. DNA migration in this case 
is proportional to the extent of DNA damage: the more serious the DNA damage, the more 
apparent the migration of DNA. Therefore, this technique can be used as a qualitative and 
quantitative instrument to detect DNA damage. For this experiment, HSC after sorting were 
resuspended in PBS+2%FBS and kept at 4°C just before the assay. Cells were pelleted and 
resuspended in a mix containing 9 volumes of 37°C melted agarose and 1 volume of room 
temperature PBS. Cells were directly spotted on comet slide and comet assay was performed 
following manufacturer’s instructions (Trevigen). After comet assay cells were stained using 
Syber-Gold dye (Thermo-Fisher Scientific) resuspended 1:10000 in cold PBS. Cells were 
stained for 10 minutes at room temperature and the excess of Syber-Gold was removed by 
two washes in water. Comets were observed with fluorescent microscope using Alexa-488 
filter, using Leica X software. Analysis of comets were performed using Autocomet, a 
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manual plugin for ImageJ, following online instructions. For quantifications, percentage of 
DNA in the tails was used as parameters. These parameter is an index of the integrity of 
DNA: the longer are the tails, the higher is the extent of DNA damage.  
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3.7 Mutation analysis 
Mutation analysis was performed using an optimized strategy that is based on the expansion 
of a single stem cell in culture giving rise to a colony. After four months of diets (SD and 
HFD), WT mice and PML/RARa KI mice were sacrificed. Total BM was isolated and 
SLAM isolation markers were used in order to identify HSC (Lin-Sca+c-Kit+Cd150+Cd48-). 
Single cells were sorted into 96-wells plates containing Lin- maintaining medium: 90% 
RPMI (Euroclone), 10% FBS for stem cell maintenance (STEMCELL Technologies), 1% 
Glutamine (Euroclone), 100 µg/ml SCF (Peprotech), 10 µg/ml IL3 (Peprotech) and 10 µg/ml 
IL6 (Peprotech), 1% Penicillin/Streptomycin (Euroclone). After two weeks of culture, 
colonies were observed using light-contrast inverted microscope (Leica) and five random 
colonies were picked. Genomic DNA was extracted using DNA micro Kit (Qiagen) 
including a step of RNase A treatment at 42°C for 10 minutes prior to the proteinase K 
treatment, in order to remove proteins and RNA contaminants. Quantification of genomic 
DNA was performed using Qubit Analyzer (Thermo Fisher Scientific) and only DNA the 
total amount of which was higher than 150 ng was sequenced. As a healthy tissue control, 
also genomic DNA from the tail was extracted using DNA mini Kit (Qiagen). 
Libraries were obtained as shown by Kozarewa and colleagues142. After library preparation, 
100 base paired-end sequencing was performed using Hiseq 2000 genome analyzer in 
accordance with the Illumina Genome Analyzer operating manual. After library preparation, 
DNA has been sequenced on 2 lanes of Illumina HiSeq2000 analyzer in paired-end mode 
with 100 bp read length. Average sequence coverage was 30x for the colonies and the tails. 
Short insert paired-end reads were aligned to the mouse reference genome (mm10) using 
Burrows-Wheeler Aligner (BWA)143 and duplicated reads were removed using 
MarkDuplicates from Picard tools [http://broadinstitute.github.io/picard/]. 
To enumerate mutations, we propose to call variants in comparison to the germline DNA 
obtained from the same animal's tail using two different algorithms: CaVEMan144(Cancer 
Variants Through Expectation Maximization) and Shearwater145. 
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CaVEMan is part of an integrated bioinformatics analysis pipeline developed at the 
Wellcome Trust Sanger Institute as part of their Cancer Genome Project (CGP). It has been 
used on a number of projects as part of the International Cancer Genome Consortium 
(ICGC).  
In detail, CaVEMan applies an expectation maximisation algorithm to call single nucleotide 
substitutions. Through comparison of reads from both tumour (data from the single stem cell 
expanded) and normal (the tail of the corresponding mouse) with the reference genome, 
CaVEMan calculates a probability for each possible genotype per base. In order to provide 
more accurate estimates of sequence error rates within the algorithm, thus aids identification 
of true variants, variables such as base quality, read position, lane, and read orientation are 
incorporated into the calculations. 
Shearwater is an approach for detecting clonal and subclonal variants; it exploits the power 
of a large sample set for precisely defining the local error rates and which uses prior 
information to call variants with high specificity and sensitivity. More in detail, Shearwater 
is built over a probabilistic framework that offers the flexibility to account for prior 
information, which turns to be useful for modeling the error distribution. The hypothesis is 
based on the observation that sequencing artifacts are recurrent on specific loci. The larger 
is the sample cohort, the better a background error distribution on each locus can be defined, 
above which true variants can be called.  
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3.8 Colony forming assay 
Colony forming assay allows the quantification of clonogenicity of HSCs. In this assay, total 
BM or stem cell subpopulations are plated in methylcellulose medium. After a short period 
(normally between 6-10 days) colonies appearing on the plates are counted on a phase 
contrast microscope (Evos Thermo-Fisher Scientific). A colony by definition derives from 
a single cell. After the count, colonies were disaggregated and cells were re-plated at the 
same cell density in methylcellulose. The procedure is repeated for multiple passages or until 
no colonies are present on the plates. Total BM cells were plated in MethoCult M3434 
(STEMCELL Technologies), a semisolid medium containing cytokines supporting the 
proliferation of stem/progenitor cells. The number of colonies mirror indirectly the number 
of pre-existing stem cells.  
 
3.8.1 Colony forming assay following SD or HFD 
To evaluate whether the diet could contribute to the increase of stem cells, we sacrificed 4 
mice per conditions: diet (HFD and SD) and genotype (WT and PML/RARα KI). BMNCs 
were plated directly in methylcellulose at a final concentration of 1*104 per plate. After 6 
days, colonies were counted on a phase contrast microscope (Evos Thermo-Fisher 
Scientific). After counting methylcellulose was dissolved in fresh medium, colonies 
disaggregated and cells counted and plated again at the same cell density. After another week 
colonies were counted again. 
 
3.8.2 Colony forming assay for FA screening 
For FA screening experiment, one PML/RARα mouse was sacrificed and processed as 
described in the 3.3.2 section. Cells were counted and plated in methylcellulose at a cell 
density of 1*104 in duplicate. Oleic Acid (Sigma-Aldrich) at a final concentration of 3.2 mM, 
Linoleic acid (Sigma-Aldrich) at a final concentration of 5 mM, and Arachidonic Acid 
(Sigma-Aldrich) at a final concentration of 5 µM were added to the methylcellulose. N.B. 
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We have demonstrated that high concentration of Arachidonic Acid is toxic for the cells. 
Ethanol and BSA were used as controls as carrier of FAs. 
 
3.8.3 Colony forming assay upon linoleic acid signalling inhibitor 
treatment 
For FAs/drug treatment experiments bone marrow cells deriving from 6-month old mice 
were plated at 1*104. FAs were used at a concentration which is present in obese mice as is 
shown in146: palmitate was used at a final concentration of 11.5 µM (we have demonstrated 
that higher concentration of palmitate is toxic for the cells), linoleic acid at 5mM. Drugs 
instead were used as reported in literature147,148: GSK 3787 (Abcam) at a final concentration 
of 10 µM, and Zileuton (Sigma-Aldrich) at 10 µM. 
 
3.8.4 Colony forming assay upon NAC treatment 
For NAC experiments, four 12-week old PML/RARα KI mice were sacrificed and BM cells 
isolated as shown. Cells were plated in MethoCult M3434 at a final concentration of 1*104 
and Linoleic Acid was used at a final concentration of 5mM. NAC (Sigma-Aldrich) was 
dissolved in sterile water and used at a final concentration of 1.5 mM as reported in the 
literature149. 
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3.9 CFSE proliferation assay  
Carboxyfluorescein succinimidyl ester (CFSE) is a dye widely used to monitor cell 
proliferation. CFSE is a small molecule that enters passively into the cells and covalently 
couples to intracellular structures. It possesses an emission spectrum similar to Alexa-488 
in FACS analysis. Given the progressive halving of CFSE fluorescence within daughter cells 
after each cell division, it can be used to mark non-dividing cells. We used CFSE to track 
cell division, in order to identify whether cells underwent symmetric/asymmetric cell 
divisions upon BSA or Linoleic acid treatment. 
Total BM cells were stained with CellTrace Proliferation Kit (Invitrogen) following 
manufacturer’s protocol. Briefly, 10*106 total BM cells were pelleted and resuspended in 1 
ml PBS. Two µl of CFSE dye were added to the cell suspension and incubated 10 minutes 
at 37°C in the dark. After incubation, cells were washed twice in PBS to remove the excess 
of dye and the fluorescence was immediately measured on FACS Celesta II. 
One week later, colonies were disaggregated and cells were pelleted at 1200 rpm and washed 
twice with PBS in order to remove medium. Cells were then resuspended in 200 µl of PBS 
and acquired on FACS Celesta II. Analysis were performed with FlowJO X software. 
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3.10 Live cell imaging 
For live cell imaging experiments, total BM cells were stained with LSK/Cd48/Cd150 
antibodies in order to isolate HSCs. One-hundred cells were then plated in MethoCult 
M3434 in the presence of BSA or 5 mM linoleic acid in 6 wells to perform live cell imaging 
with Olympus Scan R microscope, using ScanR software.   
Cells were incubated in a humidified incubator in the presence of 5% CO2 in order to sustain 
cell growth and each well was divided in 169 fields. For each field the microscope took 5 
planes for each time point which was every 6 hours for 7 days.  
After taking all the images, ScanR software was used to reconstruct the cell divisions. 
Finally, FiJi software (ImageJ), was used to isolate cells at 1,2,4,8,16 and complete colonies. 
 
3.11 Statistical analysis 
For comet assay, values were converted into arcsin for statistical analysis, the value of 
percentage was converted using the following formula: 
Arcsin (square root (Percentage/100)), Student's t test was performed on converted values, 
and since variables do not follow a normal distribution, the Mann Whitney U test was 
performed. For all other experiments two-tailed Student's t-test was performed. Graphs were 
plotted using GraphPad Prism Software. 
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Chapter 4. Results 
4.1 HFD is associated with increased DNA damage in 
HSCs 
The simplest way of explaining the cooperation between obesity and PML/RARa is a classic 
genetic model, in which HFD behaves as a carcinogen, inducing DNA mutations. Indeed, 
an increase of DNA adducts deriving from metabolism was shown to augment mutation rate 
ultimately leading to leukemia or bone marrow failure 133,134. Thus, we set up a series of 
experiments to evaluate if HFD induces adduct-mediated DNA damage and if this is fixed 
in mutations. We reasoned that prolonged low-level oxidative damage may be at play, so we 
focused on cells with prolonged life span, ie stem and progenitor cells. We started by 
analyzing whether HFD cause increased DNA damage by alkaline comet assay performed 
on HSC, progenitors and differentiated cells isolated by FACS from the BM of HFD- or SD-
fed mice 150. We used HSCs isolated from an aged-matched, UV-treated (500 uJ) mouse as 
a positive control. 
DNA damage is quantified as percentage of DNA in the tails, arcsin-transformed for 
statistical reasons (see methods for a discussion on the arcsin conversion) (Figure 7A). In 
HSC, HFD increased DNA damage both in WT (0.67 vs 0.76, p<0.0001) and in PML/RARa 
KI background (0.61 vs 0.85, p<0.0001). To better quantify the difference, each mean value 
was normalized to its own SD control. Applying this transformation, the extent of DNA 
damage appeared higher in PML/RARa (40%) than in WT (15%). These data points towards 
the existence of a cooperating mechanism between the diet and the genotype (fig. 7B). 
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Figure 7. Obesity increases the DNA damage in HSC of PML/RARα KI mice. A) 
Quantification of comet assay on HSC expressed as arcsin of percentage of DNA in the tails. 
The statistical analysis for was performed on at least 50 events for any of the 7 mice per 
experimental group, whilst the analysis on control not irradiated or irradiated animals was 
done on one mouse each. Light-blue dots represent control, blue squares irradiated control, 
grey triangles WT mice in SD, reverse dark red triangles WT HFD, black rhombuses 
PML/RARα KI mice in SD and red dots PML/RARa KI HFD. Purple lines indicate the 
average DNA damage. B) Quantification of the extent of DNA damage after normalization 
to SD. Light blue bar indicates the control, blue bar the control irradiated, grey WT SD, dark 
red WT HFD, black PML/RARα Ki SD and red PML/RARa KI HFD. ****p<0.001 
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We then asked whether the damage occurs preferentially in HSCs or ubiquitously in the 
entire BM in the PML/RARα KI background. DNA damage was also significantly increased 
in progenitor and differentiated cell fractions upon HFD but comparatively lower than in 
HSC (30% higher than SD in progenitors, 9% in differentiated cells) (Figure 8A/B). 
Thus, DNA damage is progressively resolved as cells differentiate.  
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Figure 8. Differentiated cells display less DNA damage. Quantification of DNA damage 
in HSCs, progenitors and differentiated cells deriving from PML/RARα KI mice kept in SD 
and HFD. Black rhombuses indicate the HSCs od mice in SD, red empty dots HSCs of mice 
in HFD, black dots the progenitors of mice in SD, red squares the progenitors cells of mice 
in HFD, black triangles the differentiated cells of mice in SD and red reverse triangles the 
differentiated cells of mice in HFD. D) quantification of DNA damage in progenitors and 
differentiated cells normalizing to their own controls. black bars progenitors and 
differentiated in SD, red bars progenitor and differentiated in HFD.  ****p<0.001, *p>0.05 
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4.2 HFD increases fatty acid-derived genotoxic aldehydes 
in hematopoietic stem and progenitor cells 
Oxidative attack on long-chain FA by ROS generates malondialdehyde 151, a highly reactive 
molecule that produces M1dG (pyrimido[1,2-a]purin-10(3H)-one) DNA adduct, which we 
measured in bone marrow (Lin+ and Lin- cells) from long-lived (2yr old) WT mice subjected 
to SD or HFD. It was not possible to separately analyze Lin- subpopulations as the technique 
employed requires amounts of DNA not obtainable from such rare cells. M1dG levels are 
plotted as number of nucleotides carrying the adduct per 107 nucleotides (Figure 9). No 
difference in M1dG amount in DNA deriving from Lin+ cells was shown for mice kept on 
the two diets (31 vs 24 per 107 nucleotides, p>0.05). However, a strong difference in the 
amount of the adducts was observed in the Lin- cells (7.5 in SD vs 99 in HFD per 107 
nucleotides, p<0.001). These results show that HFD induces an accumulation of genotoxic 
DNA adducts, and this occurs preferentially in undifferentiated BM cells. 
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Figure 9. M1dG adducts are increased in Lin- cells of HFD treated mice. Quantification 
of M1dG adducts per 107single nucleotides analyzed in Lin- cells (on the right) and Lin+ 
cells (on the left) of mice fed with HFD. Greyd dots represent 3 mice in SD, while red squares 
represent 3 mice in HFD. **p<0.01 
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4.3 Antioxidant supplementation decreases HFD-
associated DNA damage 
We then evaluated if the observed DNA damage was due to HFD-induced oxidative stress 
by measuring the effect of a ROS scavenger. We kept PML/RARa KI mice for four months 
on SD or HFD, with or without n-Acetylcysteine (NAC), a well-known antioxidant which 
is orally bioavailable. and well-tolerated and can be administered in drinking water 152.  
First, we monitored weight gain for four months to examine the hitherto unknown effect of 
NAC on mice weight (Figure 10). We did not detect any statistically relevant weight 
alterations in SD nor HFD upon NAC addition.  
 
Figure 10. Fold change of weight using NAC antioxidant. Fold change of weight of mice 
kept on SD or HFD and NAC measured in grams is plotted as a curve for four months. Blue 
curve represents PML/RARa KI mice in SD, orange PML/RARa KI mice in SD and NAC, 
green curve PML/RARa KI mice in HFD, black curve PML/RARa KI mice in HFD and 
NAC.  
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We then measured whether HFD and NAC treatment resulted in modulation of ROS content 
in HSCs by measuring the binding of the ROS-sensitive 2’-7’-dichlorodhydrofluorescein 
diacetate (DCDFA) dye by flow cytometry. HFD resulted in ROS level elevation, which was 
abrogated or even reduced below baseline levels by NAC treatment (Figure 11). However, 
the variability within each group was high, such that differences are not statistically 
significant and results should be considered preliminary. 
 
 
Figure 11. ROS decrease with NAC treatment. DCFDA expression was monitored in 
HSCs in two mice per condition. Mean fluorescent intensity is reported on y axis. 
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Finally, we evaluated DNA damage in HSCs by alkaline comet assay. The amount of DNA 
damage in HSCs did not change upon NAC treatment in mice fed SD. However, there was 
a 30% decrease in HSCs deriving from HFD-fed and NAC-treated mice compared to HFD 
alone (Figure 12). The decrease was so pronounced that the levels of DNA damage in HFD-
fed NAC-treated mice were comparable to those encountered in animals kept on SD 
regardless of NAC treatment. 
All together, these results suggest that HFD increases DNA damage through ROS production 
elevation. Elevated ROS may directly cause the formation of DNA adducts (M1dG) through 
lipid peroxidation.  
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Figure 12. DNA damage decreases using antioxidant agent. A) Comet quantification 
expressed as arcsin(sqr root(percentage of DNA damage)) in 4 mice per experimental 
condition. Blue dots are PML/RARa KI in SD, orange rhombuses PML/RARa KI 
SD+NAC, green dots PML/RARa KI HFD and black squared PML/RARa KI HFD+NAC. 
Red line indicates average B) fold change variation using PML/RARa KI SD as 1. Blue bar 
is PML/RARa KI SD, orange PML/RARa KI SD+NAC, green PML/RARa KI HFD and 
black PML/RARa KI is HFD+NAC. p<0.0001 **** 
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4.4 HFD does not increase frequency of mutations in pre-
leukemic HSC as revealed by Whole Genome 
Sequencing of HSC-derived clonal colonies 
We then tested if the increase in DNA damage translates into a higher number of mutations 
in HSCs. Hence, we developed a novel technique for physiologically amplifying individual 
HSC genomes, exploiting their ability to generate colonies in culture. HSCs from 
PML/RARa mice kept on HFD or SD for 4 months were single-cell sorted into 96-wells 
plates and allowed to proliferate for 2 weeks. No substantial differences in terms of colony 
formation efficiency were noticed among groups (Figure 13). Genome amplification 
obtained through cell proliferation exploits the physiological proof-reading machinery, 
circumventing the problem of elevated polymerase-associated error introduction in vitro of 
whole genome amplification 153. 
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Figure 13. Diet nor genotype influence the growth of colonies. Number of wells 
containing colonies were represented in the graph. Grey bar represents WT SD, dark red bar 
WT HFD, black bar PML/RARa KI SD and red bar PML/RARa KI HFD. 3 mice were 
analyzed per each experimental group. 
 
For each experimental condition, five colonies each from two individual mice were 
randomly picked and genomic DNA was extracted and subjected to Whole Genome 
Sequencing. As internal germline reference, genomic DNA extracted from the animal tail 
was also sequenced.  
Sequencing data were subjected to different analytical pipelines: CavEMAn154 and 
Shearwater 155. A significant difference between the two algorithms is that the former utilizes 
a matched reference to call variants (the matched tail DNA, in this case), and as such is prone 
to systematic error if a tail is sequenced to significantly different coverage than other tails. 
CavEMan variant calling pipeline includes a post-processing level able to translate a pool of 
raw variants in a set of high-confidence somatic mutations; its filters allow specificity to be 
set as high as desired to reduce the likelihood of detection of false positives in WGS data. 
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Additionally, CavEMan was recently used in the identification of physiological mosaicism 
during embryonic development144.  On the other hand, Shearwater is less prone to the bias 
of germline coverage. Indeed, the latter method is less prone to such a bias since it uses a 
pool of multiple WT references to call variants. Given the shortage of WT WGS available, 
the reference pool includes all the samples (minus the analyzed one) in any experiment, and 
thus only enumerates variants that are not in common between samples and mice. Results of 
the mutation analysis using the two different algorithms are shown in figure 14A 
(CaVEMan) and 14B (Shearwater). As expected, the two algorithms gave different results. 
Firstly, the total number of mutations differed by about an order of magnitude (max 200 vs 
60). Although CaVEMan showed a moderate diet-associated difference, this was not 
confirmed with Shearwater.  
 
A       B 
 
Figure 14. Analysis of point mutations in PML/RARa KI mice. In these two graphs are 
shown the results of mutations using CaVEMan (A) and Shearwater (B). Each colour 
corresponds to a single mouse. For each mice are 5 independent colonies were analysed 
which are shown by each bar; on y axis are reported the total number of mutations. 
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Despite differences in mutation numbers, both strategies strongly suggested that DNA 
damage does not translate into mutations.  
In addition to point mutations, we also analyzed the insertions and deletions in the genome, 
using Pindel algorithm, considering variant allele frequencies above 0.3% 156. Similarly, to 
point mutations, we could not detect any difference between the two dietary regimens 
(Figure 15) in acquisition of insertions and deletions. 
 
 
Figure 15. Analysis of deletions/insertions of PML/RARa KI mice. In the histrograms 
are shown the different colonies from 2 SD and 2 HFD PML/RARa KI mice. Blue bars 
indicate the number of insertions counted for each colony, while red bars the number of 
deletions. 
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Finally, we analyzed the amount of structural mutations, by counting the number of 
chromosomal translocations. For this purpose, breakpoint via assembly algorithm (BRASS) 
was used to detect structural variations. Only in SD2 mouse less structural variations were 
counted compared to other mice (Figure 16).  
 
Figure 16. Analysis of deletions/insertions of PML/RARa KI mice. Black dots and 
squares indicate the number of rearrangements in SD colonies, red triangles in HFD 
colonies. 
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4.5 HFD increases self-renewal of PML/RARa KI bone 
marrow cells 
The lack of a significant HFD-associated increase in DNA mutations, prompted us to 
investigate alternative mechanisms. PML/RARa is known to enhance self-renewal and 
inhibit differentiation of myeloid-committed progenitors68,157, so we investigated if HFD 
impacts stem cell properties. We performed serial replating colony forming assays in 
methylcellulose. In this assay bone marrow cells are plated in semisolid medium with 
cytokines allowing hematopoietic differentiation; the number of colonies reflects the number 
of stem-progenitor cells and the ability to maintain colony-forming activity upon serial 
passaging is considered a mirror of self-renewal. 
Whereas the assay performed on BM from WT mice revealed a reduction in colony-forming 
ability that was unaffected by diet, as expected158, BM from HFD-fed PML/RARa KI were 
able to maintain self-renewal upon serial replating, statistically significant from the second 
passage (on average 129 colonies in SD vs 276 in HFD, p<0.0001, figure 17). 
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Figure 17. PML/RARa KI BM kept in HFD shows increased clonogenicity. Total BM 
cells were plated at 104 cells/plate; after one week the resulting colonies were counted and 
the cell suspension replated at the same density. Four mice were used per condition and each 
condition was plated in triplicate. Grey dots is WT SD, dark red squares WT HFD, black 
triangles PML SD and reverse red triangles PML HFD. **p<0.001. 
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4.6 In vitro fatty acid screening suggests that unsaturated 
fatty acids enhance self-renewal 
We then tried to understand if a specific component of HFD could recapitulate HFD-induced 
enhanced self-renewal in PML/RARa KI BM. As HFD mainly differs in its content of fatty 
acids, we measured the effect if adding different FAs to semisolid medium and measured 
colony forming activity of bone marrow from SD mice We included a monounsaturated FA 
(3.2 mM oleic acid), and two polyunsaturated FA (PUFA): linoleic Acid (LA, 5 mM), the 
main unsaturated component of HFD used in the experiments and arachidonic acid (5 µM). 
The latter derives from linoleic acid and is a known mediator of general inflammation 
potentially involved in obesity-induced inflammation159. Arachidonic acid had to be used at 
lower concentrations since initial experiments showed direct cytotoxicity on bone marrow 
cells at higher concentrations. 
In cells treated with control vehicle (BSA or ethanol) the expected decrease in colony 
formation was seen at the second passage (Figure 18). Instead, increased colony formation 
was observed upon oleic acid (100 vs 300 p=0.05) and even more strongly increase upon 
linoleic acid (100 vs 446, p<0.001) addition. 
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Figure 18. Linoleic increases clonogenicity. Colonies count per 104 total bone marrow cells 
plated. Experiment was carried out in duplicate. Black dots represent control with BSA, red 
squares ET-OH, blue triangle Oleic acid, reverse green triangles linoleic acid and violet 
rhombus arachidonic acid 
 
A role for linoleic acid is consistent with the observed upregulation of linoleic acid-
metabolizing genes in promyelocyitic vs non-promyelocytic leukemias observed in the 
TCGA (see intorduction). Thus, we decided to focus on the effects of LA only. LA had no 
effect on WT BM. Importantly, adding LA with either a lipoxygenase inhibitor (Zileuton, (1 
µM) or PPARd inhibitor (GSK3787, 1 µM) completely abrogated LA-enhanced self-
renewal. This suggests that LA may mediate its activity through a direct action on PPARd 
through the generation of endogenous PPARd agonists. (Figures 19/20) 
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Figure 19. Linoleic acid induces slight increase of colonies in WT mice.  Colonies 
obtained from 104 cells plated for 3 WT mice are represented. For control, linoleic 
experiment was carried out in triplicate, while for palmitic, linoleic+GSK3787 and 
linoleic+Zileuton in duplicate. Week 1,2,3 indicate three serial platings. Black dots indicate 
WT control, red square WT treated with 11.5 µM palmitic acid, blue triangles WT treated 
with 3 mM linoleic acid, green reverse triangles WT treated with linoleic acid and GSK3787, 
and orange rhombus. *p<0.05 
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Figure 20. Linoleic acid enhances colony formation of BM cells from PML/RARa KI 
mice.  Colonies obtained for 104 cells plated for three PML/RARa KI mice are represented. 
For control, linoleic experiment was carried out in triplicate, while for palmitate, 
linoleic+GSK3787 and linoleic+Zileuton in duplicate. Black dots indicate PML/RARa KI 
control, red square PML/RARa KI treated with 11.5 µM palmitic acid, blue triangles 
PML/RARa KI treated with 5 mM linoleic acid, green reverse triangles PML/RARa KI 
treated with linoleic acid and GSK3787, and orange rhombus PML/RARa KI with Linoleic 
and Zileuton ***p<0.01. 
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We then checked if LA is required continuously for enhanced self-renewal. We performed 
an experiment in which LA was either removed or maintained after the first replating (Figure 
21).  
 
Figure 21. Experimental design. Cells from PML/RARa mice were plated in medium 
supplemented with BSA or Linoleic acid (First plating). Subsequently, cells grown in 
linoleic acid-supplemented medium were plated either with linoleic or with BSA (Second 
plating). The same media were used for the third plating. 
 
We confirmed enhanced clonogenicity upon linoleic acid treatment compared to BSA-
treated sample (134 vs 475, p<0.0001) (Figure 22). At the second passage, elimination of 
LA did not result in decreased colony formation (475 vs 479, p>0.05)., suggesting that the 
prior exposure was sufficient to enhance self-renewal. However, this was only maintained 
for one passage, since at the subsequent passage colony formation efficiency dropped 
significantly  
These data demonstrate that linoleic acid is responsible of enhanced clonogenicity and that 
it must be present continuously in order to maintain its effect.  
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Figure 22. Cells require linoleic acid to maintain their clonogenic potential. Colonies 
number for 104 total bone marrow cells. Red dots indicate cells treated with BSA, violet 
square cells treated with 5 mM linoleic acid, orange triangles cells treated with BSA after 
initial treatment with Linoleic Acid. 
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4.7 Linoleic acid-enhanced self-renewal is not due to 
increased symmetric stem cell division 
We then asked whether LA-enhanced self-renewal is due to an increased frequency of 
symmetric stem cell divisions. Since in the hematopoietic system stem cells are 
characterized by metabolic and proliferative quiescence83, the balance between symmetric 
and asymmetric stem cell divisions could be measured by quantitating the proliferative 
history upon plating. A symmetric division of a stem cell could result in either two quiescent 
or two proliferative daughter cells; an asymmetric division would result in one quiescent and 
one proliferative. However, the balance between these two proliferative modes has not been 
specifically assessed in conditions used for vitro colony forming assay. Therefore, we 
measured the cell division rates using carboxyfluorescein succinimidyl ester (CFSE) 
incorporation assay and stem cell live imaging. 
CFSE is a cell permeable dye incorporated by cells and diluted upon division, allowing to 
track proliferative history by flow cytometry. In particular, quiescent or slowly dividing cells 
maintain high levels of CFSE staining, whereas fast cycling cells lose it. Our measurements 
suggest that all cells divide actively at least 12 times (beyond which individual CFSE peaks 
are not distinguishable,) in both treatments (Figure 23) 
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Figure 23. Linoleic and BSA treated cells do no retain CFSE. A) Histogram showing BM 
cells positivity for CFSE. Light blue and red curve represent two independent mice. B) 
Histogram showing BM cells retention of CFSE after one week. Orange and red curve 
represent the cells treated with BSA, while green and light blue the cells treated with linoleic 
acid. 
 
We cannot completely rule out that asymmetric stem cell division occurs after 12 stem cell 
divisions. However, if we mathematically model this hypothesis we can easily conclude that 
this is an extremely unlikely scenario: if symmetric stem cell division occurred 12 times 
prior to the first asymmetric division, then either all the first 12 divisions were symmetric 
and gave rise to 212 stem cells, which would give rise to the same number of colonies in the 
subsequent passage, or the first division would have given rise to two non-self-renewing 
proliferating cells, which would exhaust the colony-forming potential. This is likely to 
happen in the absence of LA, but cannot happen in LA-treated cells which maintain self-
renewal upon serial replating. 
To further confirm this observation, we performed live cell imaging to directly track stem 
cell division. For this purpose, stem cells were plated in methylcellulose in the presence of 
BSA or linoleic acid. We followed cell divisions for the first four passages and counted how 
many cells were there at the end of every passage. If cells divide asymmetrically cells follow 
2n exponential growth, so that four divisions result in 16 cells. If cells divide asymmetrically, 
upon completion of a cell division, one cell enters quiescence. Thus, they would not follow 
2n exponential growth, meaning that after four division there will be less than 16 cells. Upon 
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both BSA and linoleic acid treatment, we counted 16 cells after four passages, meaning that 
all cells undergo equally timed symmetric cell divisions (Figure 24). 
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Figure 24. Linoleic does not induce symmetric HSC division. A) Live cell imaging of 
BSA treated HSCs. In the images are reported: I one cell; II two cells, III four cells; IV eight 
cells; V sixteen cells; VI entire colony. The graph reported the number of cells counted in 
four different fields; B) Live cell imaging of Linoleic Acid treated HSC. In the images are 
reported: I one cell; II two cells, III four cells; IV eight cells; V sixteen cells; VI entire 
colony. The graph reports the number of cells counted in four different fields. 
I II III IV V VI
I II III IV V VI
A
0 1 2 3 4
0
2
4
6
8
10
12
14
16
18
20
Number of divisions
N
um
be
r o
f c
el
ls
 
I II III IV V VI
I II III IV V VI
B
1 2 3 4 5
0
2
4
6
8
10
12
14
16
18
20
Number of divisions
N
um
be
r o
f c
el
ls
 85 
4.8 HFD induces HSC exit from quiescence and 
expansion of the progenitor pool 
To prove that HFD enhances self-renewal also in vivo, we measured the effect of diet on the 
number and percentage of HSC and progenitors 
An optimized flow cytometry protocol was used for the identification of progenitors and 
HSCs (See Introduction and Methods sections; fig.6). The proportion of Lin- uncommitted 
cells in the total BM ranged from 10-20%. LSK population, that includes HSCs, comprised 
about 0.2% of the total BM population. HSCs are the 0.02% of total bone marrow cells, 
while 0.18 cells are progenitors divided in HPC-1, HPC-2 and MPP (Figure 25). 
 
Figure 25. Representative result of FACS quantification of various populations in the 
BM. The arrows indicate the FACS parameters used to isolate the cells in each panel, and 
for each target the fluorophore conjugated is given in parentheses. Percentages are referred 
to the parental cells. 
 
For the purpose of this analysis, HPC1, HPC 2 and MPPs were grouped into a single category 
denominated “progenitors”. For both WT and PML/RARa KI mice, HFD caused an increase 
in progenitor numbers in agreement with previous observations152 (78% vs 85% in WT, 
p<0.01 and 73% vs 82% in PML/RARa p<0.01). In particular, HFD increased the 
percentage of HPC1/2 subpopulations. Moreover, we also observed a marked reduction in 
HSCs in WT and most markedly in PML/RARa KI mice (21% vs 14% in WT p<0.01 and 
26% vs 17%, p<0.01 in PML/RARa KI) (Figure 26).  
 
FCS
Li
n	
(P
eC
y7
)
Sca (PerCP5.5)
c-
Ki
t	(
AP
C)
Cd150	(PE)
Cd
48
	(P
ac
ifi
c	B
lu
e)
 86 
 
 
Figure 26. Obesity reduces HSC and increases progenitor numbers. A) HSCs, HCP1/2 
and MPP cells from a representative mouse per experimental branch (WT SD, WT HFD, 
PML/RARa KI SD and PML/RARa KI HFD) are shown as FACS plots.5 The fluorophore 
of each antibody is indicated in parentheses. B) Statistical analysis for the four cohorts. Grey 
dots represent WT in SD, dark red squares WT in HFD, black triangles PML/RARa KI in 
SD and reverse red triangles PML/RARa KI in HFD. For each condition 8 mice are 
represented. SD is represented with bars. **p<0.01. 
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Given that HFD decreases the percentage of HSCs and increases the percentage of 
progenitors, we wondered whether HFD would alter the balance in HSC cell cycle 
progression as assessed by DAPI staining. Ki67 staining was used to discriminate between 
G0 (Ki67-) and G1 (Ki67+). HFD was associated with a shift in cell cycle distribution 
towards increased proliferation in both genotypes, with more frequent cells in S/G2/M 
phases (5% vs 22% in WT, p>0.05 and 23.1% vs 42.85% in PML/RARa KI, p<0.05) and 
fewer in G0 and G1, although these changes were only statistically significant in the 
PML/RARα Ki background (Figure 27). Progenitors, instead, did not show any significant 
alteration in cell cycle distribution (data not shown).  
In conclusion, HFD induces HSC exit from quiescence and an increased pool of committed 
progenitors, more strongly in PML/RARa KI than in WT mice.  
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Figure 27. Obesity alters cell cycle progression in PML/RARa obese mice. Stacked 
columns showing percentages of cells in the G0, G1, S/G2/M phases of the cell cycle in WT 
SD, WT HFD, PML/RARa KI SD and PML/RARa KI HFD mice (n=2 per experimental 
class) are shown. G0 phase is shown as orange bar, G1 phase in blue bar, S/G2/M phase in 
green bar. SD are shown for each stack. *p<0.05. 
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4.9 HFD enhances in vivo self-renewal of PML/RARa KI 
HSC 
To assess if the HFD enhances HSC self-renewal also in vivo, we performed competitive 
bone marrow transplantation in syngeneic mice. In this assay, BM cells deriving from SD 
and HFD-fed PML/RARa KI mice (Cd45.2 allele variant) were mixed in 1:9 ratio with 
recipient BM cells (Cd45.1 allele variant) and transplanted into irradiated Cd45.1 recipient 
mice. The engraftment was assessed at 1 month post-transplant in the PB by measuring the 
percentages of the two allelic variants by FACS. Prior to the transplantation, the actual ratio 
was verified (Figure 28). 
 
Figure 28. Transplantation is performed at the 1:9 ratio. Example of a FACS plot of BM 
cells to be transplanted. The percentage of carrier cells marked with anti-Cd45.1 was 9 times 
higher than that of donor cells marked with anti-Cd45.2 antibody. The fluorophore 
conjugated to the specific antibody is indicated in parentheses.  
 
Six individual recipient mice per diet type were analyzed. The percentage of engrafted 
Cd45.2 cells was higher for cells deriving from HFD-fed compared to SD-fed animals. A 
representative example is shown in Figure 29A. The average percentage of engrafted Cd45.2 
cells in peripheral was 7.5% from SD-fed donors versus 18.7% from HFD-fed donors 
(p<0.001, Figure 29B). 
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Figure 29. Engraftment of SD-fed and HFD-fed mice derived BM cells in PB.  A) FACS 
plot of a representative mouse per condition deriving from SD-fed and HFD-fed donor. In 
light blue Cd45.1 are shown, in violet Cd45.2. B) 6 mouse per experimental branch are 
shown. Red bar represents Cd45.2 percentage in the PB from SD-derived mice, while blue 
bar in HFD derived mice. ** p<0.001 
 
These results, together with data obtained from ex vivo experiments clearly show that BM 
cells derived from HFD-fed mice possess a higher self-renewal ability both in vivo and in 
vitro.  
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4.10 Antioxidant treatment enhances self-renewal per se 
but does not revert HFD-associated changes 
(preliminary) 
Having demonstrated that HFD is associated with both increased ROS-dependent DNA 
damage and increased self-renewal of hematopoietic stem cells, we wished to assess if the 
two observations are related, in other words if ROS-dependent DNA damage is the cause of 
enhanced self-renewal. Therefore, we assessed the effect of NAC on self-renewal. If the 
above hypothesis is true, then NAC treatment should abolish LA- (in vitro) or HFD- (in 
vivo) enhanced self-renewal. These results are currently being replicated and should be 
considered preliminary. 
We isolated BM cells from four 12-week old PML/RARa KI mice and plated them in 
methylcellulose with BSA or linoleic acid alone or either one with NAC (at a final 
concentration of 1.5mM). For technical reasons (the only available mice were younger than 
usual, so the efficiency of colony formation was higher than expected, preventing adequate 
counting) we could only perform this first experiment for a single plating. This proved 
sufficient to observe an increased clonogenicity upon linoleic acid treatment compared to 
BSA. Strikingly, we saw that NAC treatment alone enhances self-renewal in control-treated 
samples, as we saw a rise from of colony number 104 to 171 (p<0.01) (Figure 30), but it had 
no effect on LA-treated cells. 
In vivo, we measured the percentage of HSC and progenitors in PML/RARa Ki mice fed SD 
or HFD, with or without NAC in drinking water, after 4 months of treatment. 
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Figure 30. NAC treatment enhances self-renewal. Colony number after one week of 
plating with BSA/5mM linoleic acid and 1.5mM NAC. Dark red dots are BSA treated 
samples, light blue squares Linoleic treated samples, red triangles BSA+NAC and reverse 
blue triangles LA+NAC. Four mice were used in the experiment and each condition was 
plated in duplicate. p<0.01** 
 
Again, NAC treatment leads to a decrease in HSCs and an increase in progenitors in both 
HFD and SD (Figure 31).  
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Figure 31.  NAC decreases HSC and increases progenitors. Percentage of HSCs and of 
progenitors are shown in this graph. Blue dot is PML in SD, orange squares PML SD+NAC, 
green triangles PML in HFD and reverse black triangles PML in HFD+NAC. *p<0.05, 
**p<0. 
 
Although preliminary, these results suggest that ROS-dependent DNA damage is not the 
cause for enhanced stem and progenitor self-renewal. 
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Chapter 5. Discussion and conclusions 
The final goal of this project was to understand how obesity accelerates the development of 
leukemia in a mouse model of APL. Firstly, it must be pinpointed that the mouse model we 
have currently used perfectly recapitulates the physiology of obesity in humans160, although 
we did not consider the sugar uptake that could lead to insulin resistance and finally to 
cancer161. 
The simplest theoretical model to explain the association between obesity and APL is a 
genetic model in which HFD behaves as a classic carcinogenic, generating DNA mutations 
through the induction of DNA damage. A similar model has been proposed in a different 
context by the Patel lab, who showed that endogenously generated aldehydes lead to 
leukemia or bone marrow failure, when physiological DNA repair mechanisms are 
genetically ablated133,134. Coherently with this model, in our system we observed 
accumulation of malondialdehyde-derived DNA adducts (M1dG) and DNA damage in 
hematopoietic cells from HFD-fed mice. Furthermore, the more differentiated the cells, the 
lesser the extent of DNA damage detected, supporting the idea that quiescent HSCs tolerate 
more DNA damage compared to differentiated cells, but repair damage before entering cell 
cycle130,150. Most of the DNA damage repair systems are error-prone and are considered to 
be the molecular mechanism through which mutations are fixed into the genome162. 
However, the colony WGS experiments performed here suggest that no significant increase 
in background mutation rate occurs in HSCs. Thus, the accumulated DNA damage may not 
be fixed into mutations and a purely genetic model does not seem tenable (Figure 32A). It 
must be underlined that we performed WGS only on 5 colonies deriving from 2 mice that 
could underestimate the mutation levels. Moreover, the final results of the competitive 
transplantation experiment of SD- and HFD-fed PML/RARa mice will be important: if 
recipient mice transplanted with PML/RARa KI BM from HFD-fed mice die sooner of 
leukemia than those transplanted with BM taken from SD-fed ones, it is highly possible that 
mutations arising before transplantation may have accelerated leukemia development. 
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The lack of mutations deriving from DNA damage in PML/RARa KI mice fed HFD, urged 
an investigation into alternative explanation potentially responsible for the increase in 
leukemogenesis. One such possibility is the acquisition of self-renewal, a typical property 
of stem cells, by progenitor cells thus hugely extending the pool of cells that may undergo 
malignant transformation. This hypothesis seems appealing, as it was shown that both HSCs 
and progenitors can become leukemia-initiating cells163. Indeed, APL originates from 
myeloid-committed progenitors, at least in mouse models73. Thus, long-term expansion of 
myeloid-committed progenitors in an APL-prone genetic context (provided by PML/RARa) 
may result in an expansion of the pool of potential APL-initiating cells (Figure 32B). 
Importantly, progenitor expansion per se seems not to be specific for PML/RARα, as we 
observed similar imbalances in WT HFD-fed mice. However, only PML/RARα progenitors 
derived from HFD or in the presence of linoleic acid were able to maintain colony forming 
activity over several passages. Thus, the transition from stem cell to progenitor in the obese 
or obese-mimicking environment is not accompanied by loss of self-renewal in the 
PML/RARa context. 
The molecular cause of progenitor expansion, and whether it is sufficient to explain 
increased leukemogenesis is not entirely certain. Indeed, prior data from our group131 
showed that radiation-induced DNA damage induces cell cycle entry of quiescent stem cells. 
One would imagine that DNA damage caused by the HFD metabolites is less severe, albeit 
chronic, compared to irradiation. Whether such levels of DNA damage can influence cell 
cycle entry has not been hitherto studied. However, our data suggest that this is not the case, 
since treating HFD-fed mice with antioxidants (NAC) abolished DNA damage but not 
progenitor expansion (Figure 33C). Furthermore, HFD-treated BM was more efficient at 
reconstituting secondary recipients, unlike irradiated BM152. In fact, our data show that self-
renewal is enhanced by ROS decrease (as in NAC-treated mice).  
The fact that linoleic acid, a single component of HFD, can induce enhanced self-renewal in 
vitro similarly to HFD itself suggests a more reductionist model in which linoleic acid itself, 
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and possibly other polyunsaturated FA, can directly modulate self-renewal in the presence 
of PML/RARa. 
  
 97 
 
Figure 32. Molecular models to explain how obesity accelerates APL. A) First model in 
which HFD works as carcinogen is represented. DNA damage in SD is mediated only by the 
presence of PML/RARa oncogene, while in HFD-fed mice it originates from a combination 
of HFD-deriving metabolites and the oncogene. DNA damage is then translated into 
mutations, and this explains leukemia anticipation; B) Second model in which HFD 
increases self-renewal. In this second model DNA damage increases the self-renewal ability, 
increasing in HFD the pool of cells which potentially could have the second hit and give rise 
to leukemia; C) Third model in which it is shown that self-renewal can be blocked decreasing 
DNA damage. 
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Our data are in agreement with the work of Beyaz and colleagues that have shown that HFD 
increases the stemness potential of intestinal stem cells and highlighted the role played by 
PPARd98. Current study extends their work to hematopoiesis, a different hierarchical system, 
and identifies linoleic acid as a suitable mediator for the effect of HFD. Although the 
molecular mechanism of this effect remains still poorly understood, we provide evidence for 
the involvement of the lipoxygenase pathway and PPARd. PPARd is known to functionally 
interact with PML to regulate FAO and HSC fate. Whether PPARd also interacts 
functionally with PML/RARa, and what is the molecular basis of such an interaction, 
constitute as yet unexplored questions onto which this work has started to shed some light. 
LA-derived metabolites (which require lipoxygenase activity164) can act as PPAR activators, 
although most evidence has been gathered for the structurally related PPARg. 
The presence of PML/RARa imposes a differentiation block at the promyelocyte stage 
through transcriptional deregulation mediated by interaction of PML/RARa with epigenetic 
modifiers and transcription factors. Importantly, RARa, PML/RARa and PPAR factors all 
require interaction with RXR for their transcriptional activity, so that RXR-mediated 
molecular interactions may be the key to the mechanism under investigation. Based on our 
data, we can speculate that upon interaction with LA-derived PPARd activators, 
PML/RARa-imposed differentiation block becomes more effective, to a degree able to 
trigger the leukemic phenotype. Key to this mechanism may be the interaction with different 
chromatin modifiers of PML/RARa and PPARd. Future experiments should aim at 
characterizing diet-associated differences in epigenetic features and PML/RARa and 
PPARd interaction complexes. These experiments may reveal novel strategies for 
therapeutic targeting. 
An important consequence of this model is that the interaction between HFD and 
PML/RARa may be reversible, so that dietary modifications aimed at reducing 
polyunsaturated fat levels may have a therapeutic or preventive effect. We have extensively 
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explored these hypotheses in a parallel work, not shown here, in which we show that caloric 
restriction in mice, i.e. polyunsaturated FA intake limitation, does, in fact, lead to a delayed 
leukemia onset and prolonged survival when used therapeutically. 
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Appendix 
Relevant pubblication 
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an 
immunosuppressive ILC2-MDSC axis. 
 
 Trabanelli S, Chevalier MF, Martinez-Usatorre A, Gomez-Cadena A, Salomé B, Lecciso 
M, Salvestrini V, Verdeil G, Racle J, Papayannidis C, Morita H, Pizzitola I, 
Grandclément C, Bohner P, Bruni E, Girotra M, Pallavi R, Falvo P, Leibundgut EO, 
Baerlocher GM, Carlo-Stella C, Taurino D, Santoro A, Spinelli O, Rambaldi A, 
Giarin E, Basso G, Tresoldi C, Ciceri F, Gfeller D, Akdis CA, Mazzarella L, 
Minucci S, Pelicci PG, Marcenaro E, McKenzie ANJ, Vanhecke D, Coukos G, 
Mavilio D, Curti A, Derré L, Jandus C. 
 
Nat. Commun. 2017 
Abstract 
Group 2 innate lymphoid cells (ILC2s) are involved in human diseases, such as allergy, 
atopic dermatitis and nasal polyposis, but their function in human cancer remains 
unclear. Here we show that, in acute promyelocytic leukaemia (APL), ILC2s are 
increased and hyper-activated through the interaction of CRTH2 and NKp30 with 
elevated tumor-derived PGD2 and B7H6, respectively. ILC2s, in turn, activate 
monocytic myeloid-derived suppressor cells (M-MDSCs) via IL-13 secretion. Upon 
treating APL with all-trans retinoic acid and achieving complete remission, the 
levels of PGD2, NKp30, ILC2s, IL-13 and M-MDSCs are restored. Similarly, 
disruption of this tumor immunosuppressive axis by specifically blocking PGD2, 
IL-13 and NKp30 partially restores ILC2 and M-MDSC levels and results in 
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increased survival. Thus, using APL as a model, we uncover a tolerogenic pathway 
that may represent a relevant immunosuppressive, therapeutic targetable, 
mechanism operating in various human tumor types, as supported by our 
observations in prostate cancer.Group 2 innate lymphoid cells (ILC2s) modulate 
inflammatory and allergic responses, but their function in cancer immunity is still 
unclear. Here the authors show that, in acute promyelocytic leukaemia, tumor-
activated ILC2s secrete IL-13 to induce myeloid-derived suppressor cells and 
support tumor growth. 
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Congress abstracts 
1. Inhibition of the Histone Demethylase LSD1 Combined with 
Caloric Restriction or IGF1/Insulin Inhibition Leads to Durable 
Responses in a Preclinical Model of Acute Myeloid Leukemia 
Luca Mazzarella, Tiphanie Durfort, Rani Pallavi, Elena Mylonas, Paolo Falvo, Anna 
Giulia Sanarico, Massimo Stendardo, Luciano Giaco', Anna Russo, Lucilla Luzi, 
Massimiliano Mazza, Giulia De Conti, Paola Vianello, Pier Luigi Rossi, Elena Ceccacci, 
Mohamed Elgendy, Marco Giorgio, Ciro Mercurio, Saverio Minucci and Pier Giuseppe 
Pelicci 
American Society of Hematology (ASH) 5-7 December 2015, Orlando (FL) 
 
Abstract 
Introduction. There is increasing interest in therapeutic modulation of metabolic pathways 
in cancer. Tumor cells preferentially use aerobic glycolysis to meet their energetic demands. 
However, glycolysis inhibition alone is unable to bring durable responses because of limited 
therapeutic index and because of previously underappreciated metabolic adaptability in 
tumor cells, which can switch to alternative substrate usage when specific nutrients are 
limiting. The molecular basis of metabolic adaptation is poorly understood. Recently, the 
histone demethylase LSD1 (Lysine-Specific Demethylase 1) has been implicated in the 
control of oxidative phosphorylation (OXPHOS) in adipocytes through its interaction with 
NRF1 (Nuclear Respiratory Factor 1), a master regulator of metabolic gene transcription (1). 
We hypothesized that LSD1 could regulate metabolic adaptability and be a therapeutic target 
upon metabolic modulation through Caloric Restriction (CR) in Acute Myeloid Leukaemia 
(AML) and specifically in APL (Acute Promyelocytic Leukaemia), which we showed to be 
sensitive to body fatness in the clinic (2). 
Methods. APLs were generated in mice expressing the PML-RARa fusion under the control 
of the Cathepsin G promoter (3). Primary leukemias were transplanted into recipients 
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subjected to 30% CR or Standard Diet (SD). We scored the effect of CR alone or in 
combination with the LSD1 inhibitor IEO368 (4) on mouse survival, Leukemia Initiating 
Cell (LIC) frequency and epigenomic, transcriptomic and metabolic parameters. 
Results. Compared to SD controls, CR-fed recipients experienced an initial dramatic 
decrease in the total leukemic burden accompanied by cell cycle slowdown (“adaptation 
phase”); this was followed by a delayed disease progression that brought animals to death 
(“terminal phase”) (median survival 91 vs 51 days, p=0.038). Limiting-dilution 
transplantation of CR-conditioned leukemias revealed increased frequency of LICs 
(estimated frequency 1/3064 cells in SD vs 1/947 in CR, p=0.003) and increased 
aggressiveness (median survival reduced to 49 vs 70.5 days with 5000 cells injected, 
p<0.0001). Thus, CR limits the expansion of leukemic cells but enriches for cells with 
increased ability to regrow.RNAseq of leukemic cells purified during the terminal phase (but 
not earlier) showed that a dramatic transcriptional reprogramming in CR, characterized by 
upregulation of genes controlling OXPHOS, Krebs cycle and nucleotide and protein 
biosynthesis, and downregulation of insulin signaling and glucose transporters. Flow 
cytometry with Mitotracker Red confirmed increased mitochondrial activity. Thus, leukemic 
cells exposed to CR put in place adaptive transcriptional changes to allow survival in a 
nutrient/growth factor deprived environment.To investigate the basis of these transcriptional 
changes, we revised ChIPseq analysis of LSD1 binding in human APL cell lines and found 
a significant enrichment for i) NRF1 consensus binding motif and ii) promoters of genes 
encoding for OXPHOS and Krebs cycle enzymes. NRF1 binding to OXPHOS/Krebs 
enzymes was confirmed on mouse leukemias by ChIPseq. These data suggested that the CR-
induced adaptive changes could be mediated by LSD1/NRF1.Strikingly, co-treatment of 
leukemic mice with CR and our LSD1 inhibitor IEO368 (4) resulted in macroscopic and 
microscopic eradication of disease (see figure, p=0.0018 compared to SD). In these 
conditions, leukemic cells completely disappeared in 4/6 mice after 4 weeks. LSD1 
inhibition alone was also effective but did not produce bona fide disease eradication. 
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Importantly, some of the features of the CR-LSD1 interaction could be modeled by 
combining LSD1 and an IGF1/Insulin inhibitor. In vivo, this combination was synergistic 
and led to durable responses (median survival 121 vs 50 days in untreated controls, 
p=0.0143, vs 65.5 and 78.5 days with Insulin/IGF1 Inhibitor and IEO368 respectively). 
Conclusion: the combination of LSD1 inhibition and insulin/IGF1 signaling reduction by 
pharmacological or dietary intervention appears as a highly effective therapeutic strategy 
and deserves further investigation. Ongoing preclinical studies will verify its applicability to 
other models of AML. 
References: 
1. Duteil et al, Nat Commun. 2014 Jun 10;5:4093 
2. Breccia et al, Blood. 2012 Jan 5;119(1):49-54 
3. Westervelt et al, Blood. 2003 Sep 1;102(5):1857-65 
4. Varasi et a,l Eur J Cancer Vol 50 supp 6: 185 
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2. Novel role of obesity in the development of acute promyelocitic 
leukaemia 
Paolo Falvo, Luca Mazzarella, Anna G. Sanarico, Elena Gatti and Pier Giuseppe Pelicci 
Enable Congress, Barcelona, oral presentation. 15-17 November 2017 
Abstract 
 
Obesity is defined as a pathological state characterized by an augmented presence of fat 
mass in the body. It is widely known that obesity increases the risk of many cancer types.[1] 
Clinical data have shown that obesity is strongly correlated with acute promyelocytic 
leukaemia (APL). These leukaemias carry a reciprocal translocation between the retinoic 
acid receptor α (RARα) and PML genes, giving rise to the formation of a fusion protein 
PML/RARα. However, the molecular mechanisms underlying the effects of obesity on APL 
development are not elucidated. 
To recapitulate clinical observations, we aimed at developing and characterizing a mouse 
model of diet-induced obesity. We used transgenic mice expressing constitutively 
PML/RARα in hematopoietic system (PML/RARα KI mice) and wild type mice as control.[2] 
Mice were treated with two different diets: standard diet (SD) and high fat diet (HFD) (60% 
vs 10% of fats in the chow), and leukaemia free survival was monitored. Interestingly, we 
observed that PML/RARα KI treated with HFD developed leukaemia earlier (median 
survival 204 vs 254 days, p<0.001) and with higher penetrance (100% vs 70%), as compared 
to the same mice treated with SD.  
We also evaluated the extent of DNA damage in hematopoietic stem cells (HSC) after 
four months of diet, using the comet assay. Along with a shorter survival time, we also 
demonstrated that HFD PML/RARα KI mice present 40% increase of DNA damage in HSC 
as compared to SD PML/RARα mice (p<0.001). Finally, we scored whether the diet confers 
proliferative advantage to PML/RARα bone marrow using colony forming cell assay. We 
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observed that HFD PML/RARα bone marrow has a stronger clonogenic activity as compared 
to SD PML/RARα bone marrow (mean 269 ± 61 in SD and 1170 ± 482 in HFD) (p<0.01). 
Our data suggest that HFD has a double role in PML/RARα KI mice: it increases the 
penetrance and decreases the latency. Moreover, we demonstrated that the diet increases the 
amount of DNA damage in HSC of PML/RARα mice and also the clonogenic capacity of 
PML/RARα bone marrow. 
 
[1] Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L. Lancet. 
(2014); 755-65 
[2] Grisolano JL, Wesselschmidt RL, Pelicci PG, Ley TJ.  Blood. (1997); 376-87 
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3. Obesity favours leukemogenesis through enhanced preleukemic 
stem cell self-renewal via polyunsaturated fatty acid-dependent ER 
stress relief 
Luca Mazzarella, Paolo Falvo, Annagiulia Sanarico, Elena Gatti and Piergiuseppe Pelicci 
 
American Association for Cancer Research (AACR) Annual Meeting, 14-18 April 2018 
Chicago 
Abstract 
Obesity increases risk for multiple tumors, but impact on leukemia and its underlying 
molecular mechanism are poorly understood. Studies from our group and others showed that 
risk and outcome of Acute Promyelocytic Leukemia (APL) are more strongly associated 
with obesity than other hematological neoplasms. Intriguingly, in 2 independent cohorts 
(Italian and TCGA), obesity was associated with ~4 fold higher incidence of internal tandem 
duplications of the leukemogenic kinase FLT3 (FLT3-ITD), the first example of obesity-
associated genetic alterations in cancer (unpublished). Here we propose a molecular 
mechanisms underlying obesity-associated leukemogenesis through our studies in murine 
models. Exposure to High fat Diet (HFD), an established model of obesity-related pathology, 
strongly accelerated disease onset and mortality in 3 murine models of hematological cancer: 
PML-RARa knockin (PRKI), developing an APL-mimicking disease; FLT3ITD knockin 
(FIKI) developing myeloproliferation; a new double PRKI-FIKI knockin mouse, developing 
APL-like disease but, surprisingly, with delayed latency compared to PRKI, presumably due 
to the known exhaustion of hematopoietic stem cells (HSC) associated with FLT3ITD. 
Preleukemic HSCs from HFD PRKI mice showed increased DNA damage in Comet assays, 
but surprisingly this was not associated with increased mutational load as revealed by a novel 
whole genome sequencing-based method. Instead, HSCs derived from HFD PRKI mice 
showed enhanced self-renewal in in vitro replating assays. Similarly, in the FIKI model we 
observed enhanced engraftment in serial competitive transplantation experiments in HFD-
fed recipients. Delving more deeply in the molecular mechanisms, through bioinformatic 
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analysis of RNAseq data from the TCGA we found upregulation of the linoleic acid (LA) 
pathway in obese APL patients. LA is the richest fatty acid in HFD and in many western 
diets, thus a likely candidate for mediating HFD activity. LA significantly enhanced PRKI 
serial replating efficiency; this was abolished by pharmacologically blocking LA 
metabolism through a 5-lipoxygenase inhibitor or its transcriptional effects through a 
PPARd inhibitor. In the FIKI model and in a FLT3ITD-inducible cell line, we revealed a 
previously unappreciated induction of ER stress by FLT3ITD, likely to underlie FLT3ITD-
induced HSC exhaustion. HFD (in vivo) and LA (in vitro) relieved FLT3ITD-induced ER 
stress, as revealed by the attenuation of markers of adaptive response to ER stress (Unfolded 
Protein Response and RNA IRE1-dependent RNA decay). In conclusion, our study suggests 
a novel and somewhat counterinuitive model for obesity-associated cancerogenesis: rather 
than inducing cellular stress, HFD-induced obesity enhances the self-renewal of preleukemic 
stem cells through LA-mediated alleviation of oncogene-induced proteotoxic stress 
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